<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        193-325-07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RIASERTAL 100 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SERTRALINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        191.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Riasertal contains the active substance sertraline. Sertraline is one of a group of medicines called Selective Serotonin Re-uptake Inhibitors (SSRIs); these medicines are used to treat depression and/or anxiety disorders.</p><p><strong>Riasertal can be used to treat:</strong></p><ul><li>Depression and prevention of recurrence of depression (in adults).</li><li>Social anxiety disorder (in adults).</li><li>Post traumatic stress disorder (PTSD) (in adults).</li><li>Panic disorder (in adults).</li><li>Obsessive compulsive disorder (OCD) (in adults and children and adolescents aged 6-17 years old).</li></ul><p>Depression is a clinical illness with symptoms like feeling sad, unable to sleep properly or to enjoy life as you used to.</p><p>OCD and Panic disorders are illnesses linked to anxiety with symptoms like being constantly troubled by persistent ideas (obsessions) that make you carry out repetitive rituals (compulsions).</p><p>PTSD is a condition that can occur after a very emotionally traumatic experience, and has some symptoms that are similar to depression and anxiety. Social anxiety disorder (social phobia) is an illness linked to anxiety. It is characterised by feelings of intense anxiety or distress in social situations (for example: talking to strangers, speaking in front of groups of people, eating or drinking in front of others or worrying that you might behave in an embarrassing manner).</p><p>Your doctor has decided that this medicine is suitable&nbsp; for treating your illness.</p><p>You should ask your doctor if you are unsure why you have been given Riasertal.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>Do not take Riasertal:</strong></p><ul><li>If you are allergic to sertraline or any of the other ingredients of this medicine (listed in section 6).</li><li>If&nbsp; you &nbsp;are &nbsp;taking&nbsp; or &nbsp;have &nbsp;taken &nbsp;medicines&nbsp; called monoamine oxidase inhibitors (MAOIs such as selegiline, moclobemide) or MAOI like drugs&nbsp; (such as linezolid). If you stop treatment with setraline, you must wait until at least one week before you start treatment with a MAOI. After stopping treatment with a MAOI, you must wait at least 2 weeks before you can start treatment with sertraline.</li><li>If you are taking another medicine called pimozide (a medicine for mental disorders such as psychosis).</li></ul><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Riasertal. Medicines are not always suitable for everyone.</p><p>Tell your doctor before you take Riasertal, if you suffer from or have suffered in the past from any of the following conditions:</p><ul><li>If you have epilepsy (fit) or a history of seizures. If you have a fit (seizure), contact your doctor immediately.</li><li>If you have suffered from manic-depressive illness (bipolar disorder) or schizophrenia. If you have a manic episode, contact your doctor immediately.</li><li>If you have or have previously had thoughts of harming or killing yourself, (see below-Thoughts of suicide and worsening of your depression or anxiety disorder).</li><li>If you have Serotonin Syndrome. In rare cases, this syndrome may occur when you are taking certain medicines at the same time as sertraline. (For symptoms, see section 4. Possible Side Effects). Your doctor will have told you whether you have suffered from this in the past.</li><li>If you have low sodium level in your blood, since this can occur as a result of treatment with Riasertal. You should also tell your doctor if you are taking certain medicines for hypertension, since these medicines may also alter the sodium level in your blood.</li><li>If you are elderly as you may be more at risk of having low sodium level in your blood (see above).</li><li>If you have liver disease, your doctor may decide that you should have a lower dose of Riasertal.</li><li>If you have diabetes; your blood glucose levels may be altered due to Riasertal and your diabetes medicines may need to be adjusted.</li><li>If you have suffered from bleeding disorders or have been taking medicines, which thin the blood (e.g. acetylsalicylic acid (aspirin), or warfarin) or may increase the risk of bleeding.</li><li>If you are a child or adolescent under 18 years old. Riasertal should only be used to treat children and adolescents aged 6 - 17 years old, suffering from obsessive-compulsive disorder (OCD). If you are being treated for this disorder, your doctor will want to monitor you closely (see below Children and adolescents).</li><li>If you are having electro-convulsive therapy (ECT).</li><li>If you&nbsp; have eye&nbsp; problems, such&nbsp; as certain kinds&nbsp; of glaucoma (increased pressure in the eye).</li><li>If you have been told that you have an abnormality of your heart tracing after an electrocardiogram (ECG) known as prolonged QT interval.</li></ul><p><strong>Restlessness/Akathisia:</strong></p><p>The use of sertraline has been linked to a distressing restlessness and need to move, often being unable to sit or stand still (akathisia). This is most likely to occur during the first few weeks of treatment. Increasing the dose may be harmful so if you develop such symptoms you should talk to your doctor.</p><p><strong>Withdrawal &nbsp;reactions:</strong></p><p>Side effects relating to stopping treatment (withdrawal reactions) &nbsp;are &nbsp;common, &nbsp;particularly &nbsp;if &nbsp;the &nbsp;treatment is stopped suddenly (see section 3 If you stop taking Riasertal and section 4 Possible side effects). The risk of withdrawal symptoms depends on the length of treatment, dosage, and the rate at which the dose is reduced. Generally, such symptoms are mild to moderate. However, they can be serious in some patients. They &nbsp;normally occur within the first few days after stopping treatment. In&nbsp;general, such symptoms disappear on their own and wear off within 2 weeks. In some patients, they may last longer (2-3 months or more). When stopping treatment with sertraline, it is recommended to reduce the dose gradually&nbsp; over a period of several weeks or months, and you should&nbsp; always discuss the best way of stopping treatment with your doctor.</p><p><strong>Thoughts of suicide and worsening of your depression or anxiety disorders:</strong></p><p>If you are depressed &nbsp;and/or &nbsp;have &nbsp;anxiety &nbsp;disorders, you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.</p><p><strong>You may be more likely to think like this:</strong></p><ul><li>If you have previously had thoughts about killing or harming yourself.</li><li>If you are a young adult. Information from clinical trials has shown &nbsp;an &nbsp;increased &nbsp;risk &nbsp;of &nbsp;suicidal &nbsp;behaviour in adults&nbsp; aged&nbsp; less&nbsp; than&nbsp; 25&nbsp; years&nbsp; with&nbsp; psychiatric conditions who were treated with an antidepressant.</li></ul><p>If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away. You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behavior.</p><p><strong>Children and adolescents:</strong></p><p>Sertraline should not usually be used in children and adolescents less than 18 years old, except for patients with Obsessive Compulsive Disorder (OCD). Patients under 18 have an increased risk of undesirable effects, such as suicide attempt, thoughts of harming or killing themselves (suicidal thoughts) and hostility (mainly aggressiveness, oppositional behaviour and anger) when they are treated with this class of medicines. Nevertheless, it is possible that your doctor decides to prescribe Riasertal to a patient under 18 if it is in the patient&#39;s interest. If your doctor has prescribed Riasertal to you and you are less than 18 years old and you want to discuss this, please contact him/her. Furthermore, if any of the symptoms listed above appear or worsen while you are taking Riasertal, you should inform your doctor. Also, the long-term safety of Riasertal in regard to growth, maturation and learning (cognitive) and behavioural development in this age group has not yet been demonstrated.</p><p><strong>Other medicines and Riasertal:</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Some medicines can &nbsp;affect &nbsp;the &nbsp;way &nbsp;Riasertal &nbsp;works, or Riasertal itself can reduce the effectiveness of other medicines taken at the same time.</p><p>Taking Riasertal together with the following medicines may cause serious side effects:</p><ul><li>Medicines called monoamine oxidase inhibitors (MAOIs), like moclobemide (to treat depression) and selegiline (to treat Parkinson&#39;s disease), the antibiotic linezolid and methylene blue (to treat high levels of methaemoglobin in the blood). Do not use Riasertal together with these medicines.</li><li>Medicines to treat mental disorders such as psychosis (pimozide). Do not use Riasertal together with pimozide.</li></ul><p><strong>Talk to your doctor if you are taking the following medicines:</strong></p><ul><li>Herbal medicine containing St. John&#39;s Wort (Hypericum perforatum). The effects of St. John&#39;s Wort may last for 1-2 weeks.</li><li>Products containing the amino acid tryptophan.</li><li>Medicines to treat severe pain (e.g. tramadol).</li><li>Medicines used in anaesthesia or to treat chronic pain (fentanyl).</li><li>Medicines to treat migraines (e.g. sumatriptan).</li><li>Blood thinning medicine (warfarin).</li><li>Medicines to treat pain/arthritis (Non steroidal anti-inflammatory drug (NSAID) such as ibuprofen, acetylsalicylic acid (aspirin).</li><li>Sedatives (diazepam).</li><li>Diuretics (also called &#39;water&#39; tablets).</li><li>Medicines to treat epilepsy (phenytoin, phenobarbital, carbamazepine).</li><li>Medicines to treat diabetes (tolbutamide).</li><li>Medicines to treat excessive stomach &nbsp;acid, &nbsp;ulcers and heartburn (cimetidine, omeprazole, lanzoprazole, pantoprazole, rabeprazole).</li><li>Medicines to treat mania and depression (lithium).</li><li>Other medicines to treat depression (suc as amitriptyline, nortriptyline, nefazodone, fluoxetine, fluvoxamine).</li><li>Medicines to treat schizophrenia and other mental disorders (such as perphenazine, levomepromazine and olanzapine).</li><li>Medicines used to treat high blood pressure, chest pain or regulate the rate and rhythm of the heart (such as verapamil, diltiazem, flecainide, propafenone).</li><li>Medicines used to&nbsp; treat bacterial infections&nbsp; (such as rifampicin, clarithromycin, telithromycin, erythromycin).</li><li>Medicines used to treat fungal infections (such as ketoconazole, itraconazole, posaconazole, voriconazole, fluconazole).</li><li>Medicines used to treat HIV/AIDS and Hepatitis C (protease inhibitors such as ritonavir, telaprevir).</li><li>Medicines used to prevent nausea and vomiting after an operation or chemotherapy (aprepitant).</li><li>Medicines known to increase the risk of changes in the electrical activity of the heart (e.g. some antipsychotics and antibiotics).</li></ul><p><strong>Riasertal with food, drink and alcohol:</strong></p><p>Riasertal tablets can be taken with or without food.</p><p>Alcohol should be avoided whilst taking Riasertal. Sertraline &nbsp;should &nbsp;not &nbsp;be &nbsp;taken &nbsp;in &nbsp;combination &nbsp;with grapefruit juice, as this may increase the level of sertraline in your body.</p><p><strong>Pregnancy, breast-feeding and fertility:</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>The safety of sertraline has not fully been established in pregnant women. Sertraline will only be given to you when pregnant if your doctor considers that the benefit for you is greater than any possible risk to the developing baby. If you are a woman capable of having children you should use a reliable method of contraception (such as the contraceptive pill), when taking sertraline.</p><p>Make sure your midwife and/or doctor know you are on Riasertal. When taken during pregnancy, particularly in the last 3 months of pregnancy, medicines like Riasertal may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby, you should contact your midwife and/or doctor immediately.</p><p>Your newborn baby&nbsp; might also&nbsp; have other&nbsp; conditions, which usually begin during the first 24 hours after birth. Symptoms include:</p><ul><li>Trouble with breathing,</li><li>A bluish skin or being too hot or cold,</li><li>Blue lips,</li><li>Vomiting or not feeding properly,</li><li>Being very tired, not able to sleep or crying a lot,</li><li>Stiff or floppy muscles,</li><li>Tremors, jitters or fits,</li><li>Increased reflex reactions,</li><li>Irritability,</li><li>Low blood sugar.</li></ul><p>If your baby has any of these symptoms when it is born, or you are concerned about your baby&#39;s health, contact your doctor or midwife who will be able to advise you.</p><p>There is evidence that sertraline passes into human breast milk. Sertraline should only be used in women during breast-feeding; if your doctor considers that, the benefit exceeds any possible risk to the baby.</p><p>Some medicines like sertraline may reduce the quality of sperm in animal studies. Theoretically, this could affect fertility, but impact on human fertility has not been observed yet.</p><p>Driving and using machines:</p><p>Psychotropic drugs such as sertraline may influence your a&nbsp;ability to drive or use machines. You should therefore not drive or operate machinery, until you know how this medication affects your ability to perform these activities.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>The recommended dose is: </strong></p><p><strong>Adults:</strong></p><p><em><strong>Depression</strong><strong> </strong><strong>and Obsessive Compulsive Disorder</strong></em></p><p>For depression and OCD, the usual effective dose is 50 mg/day. The daily dose may be increased in 50 mg increments and at intervals of at least one week over a period of weeks. The maximum recommended dose is 200 mg/day.</p><p><strong><em>Panic disorder, Social anxiety disorder and Post Traumatic Stress Disorder:</em></strong></p><p>For panic disorder, social anxiety disorder and post traumatic stress disorder, treatment should be started at 25 mg/day, and increased to 50 mg/day after one week. The daily dose then may be increased in 50 mg increments over a period of weeks. The maximum recommended dose is 200 mg/day.</p><p><strong><em>Use in children and adolescents:</em></strong></p><p>Riasertal must only be used to treat children and adolescents suffering from OCD aged 6-17 years old.</p><p><strong>Obsessive Compulsive Disorder:</strong></p><p><strong><em>Children aged 6 to 12</em>: </strong>the recommended starting dose is 25 mg daily.</p><p>After one week, your doctor may increase this to 50 mg daily. The maximum dose is 200 mg daily.</p><p><strong><em>Adolescents aged 13 to 17</em>: </strong>the recommended starting dose is 50 mg daily. The maximum dose is 200 mg daily.</p><p>If you have liver or kidney problems, please tell your doctor and follow the doctor&#39;s instructions.</p><p><strong>Method of administration:</strong></p><p>Riasertal tablets may be taken with or without food.</p><p>Take your medication once daily either in the morning or evening.</p><p>Your doctor will advise you on how long to take this medication. This will depend on the nature of your illness and how well you are responding to the treatment. It may take several weeks before your symptoms begin to improve. Treatment of depression should usually continue for 6 months after improvement.</p><p><strong>If you take more Riasertal than you should:</strong></p><p>If you accidentally take too much Riasertal contact your doctor at once or go to the nearest hospital casualty department. Always take the labelled medicine package with you, whether there is any medication left or not. Symptoms of overdose may include drowsiness, nausea and vomiting, rapid heart rate, shaking, agitation, dizziness and in rare cases unconsciousness.</p><p><strong>If you forget to take Riasertal:</strong></p><p>Do not take a double dose to make up for a forgotten dose. If you forget to take a dose, do not take the missed dose. Just take the next dose at the right time.</p><p><strong>If you stop taking Riasertal:</strong></p><p>Do not stop taking Riasertal unless your doctor tells you to. Your doctor will want to gradually reduce your dose of Riasertal over several weeks, before you finally stop taking this medicine. If you suddenly stopped taking this medicine, you may experience side effects such as dizziness, numbness, sleep disturbances, agitation or anxiety, headaches, feeling sick, being sick and shaking. If you experience any of these side effects, or any other side effects whilst stopping taking Riasertal, please speak to your doctor.</p><p><strong>If you&nbsp; have any further questions&nbsp; on the use of&nbsp; this product, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Nausea is the most common side effect. The side effects depend on the dose and often disappear or lessen with continued treatment.</p><p><strong>Tell your doctor immediately:</strong></p><p>If you experience any of the following symptoms after taking this medicine, these symptoms can be serious.</p><ul><li>If you develop a severe skin rash that causes blistering (erythema multiforme), (this can affect the mouth and tongue). These maybe signs of a condition known as Stevens Johnson Syndrome, ot Toxic Epidermal Necrolysis (TEN). You doctor will stop your treatment&nbsp; in these cases.</li><li>Allergic reaction or allergy, which may include symptoms such as an itchy skin rash, breathing problems, wheezing, swollen eyelids, face or lips.</li><li>If you experience agitation, confusion, diarrhoea, high temperature and blood pressure, &nbsp;excessive &nbsp;sweating and rapid heartbeat. These are symptoms of Serotonin Syndrome. In rare cases this syndrome may occur when you are taking certain medicines at the same time as sertraline. Your doctor may wish to stop your treatment.</li><li>If you develop yellow skin and eyes which may mean liver damage.</li><li>If you experience depressive symptoms with ideas of harming or killing yourself (suicidal thoughts).</li><li>&nbsp;If you start to get feelings of restlessness and are not able to sit or stand still after you start to take Riasertal. You should tell your doctor if you start to feel restless.</li><li>If you have a fit (seizure).</li><li>If you have a manic episode (see section 2 &quot;Warnings and precautions&quot;).</li></ul><p><strong>The following side effects were seen in clinical trials in adults:</strong></p><p><strong>Very common (may affect more than 1 in 10 people):</strong> Insomnia, &nbsp;dizziness, &nbsp;sleepiness, &nbsp;headache, &nbsp;diarrhoea, feeling sick, dry mouth, ejaculation failure, fatigue.</p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><ul><li>Sore throat, anorexia, increased appetite,</li><li>Depression, feeling strange, nightmare, anxiety, agitation, nervousness, decreased sexual interest, teeth grinding,</li><li>Numbness and tingling, shaking, muscle tense, abnormal taste, lack of attention,</li><li>Visual disturbance, ringing in ears,</li><li>Palpitations, hot flush, yawning,</li><li>Abdominal pain, vomiting, constipation, upset stomach, gas,</li><li>Rash, increased sweating, muscle pain, erectile dysfunction, chest pain</li><li>Joint pain,</li><li>Malaise.</li></ul><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><ul><li>Chest cold, runny nose,</li><li>Hypersensitiveity,</li><li>Low thyroid hormones,</li><li>Hallucination, feeling too happy, lack of caring, thinking abnormal, aggression,</li><li>Convulsion, involuntary muscle contractions, abnormal coordination, moving a lot, amnesia, decreased feeling, speech disorder, dizziness while standing up, passing out, migraine,</li><li>Enlarged pupils,</li><li>Ear pain, fast heartbeat, high blood pressure, flushing,</li><li>Breathing diffculty, possible wheezing, shortness of breath, nose bleed,</li><li>Inflammation of the oesophagus, diffculty swallowing, haemorrhoids, increased saliva, tongue disorder, burping,</li><li>Eye swelling, purple spots on skin, face oedema, hair loss, cold sweat, dry skin, hives, itching,</li><li>Osteoarthritis, muscular weakness, back pain, muscle twitching,</li><li>Night-time urination, unable to urinate, increase in urination, increase in frequency of urination, problem urinating, urinary incontinence,</li><li>Vaginal haemorrhage, sexual dysfunction, female sexual dysfunction, menstrual&nbsp; irregularities, swelling in legs, chills, fever, weakness, thirst, increase in liver enzyme levels, weight decreased, weight increased. enzyme levels, weight decresed, weight increased.</li></ul><p><strong>Rare (may affect up to 1 in 1,000 people):</strong></p><ul><li>Intestine problem, ear infection, cancer, swollen glands, high cholesterol, low blood sugar,</li><li>Physical symptoms due to stress or emotions, drug dependence, psychotic disorder, paranoia, suicidal thoughts, sleep walking, premature ejaculation,</li><li>Severe allergic reaction,</li><li>Coma, abnormal movements, difficulty moving , increased sensation, sensory disturbance.</li><li>Glaucoma, tear problem, spots in front of eyes, double vision, light hurts eye, blood in the eye, problems controlling blood sugar levels (diabetes),</li><li>Heart attack, slow heart beat, heart problem, poor circulation of arms and legs, closing up of throat, breathing fast, breathing slow, diffculty &nbsp;talking, hiccups,</li><li>Blood in stool, sore mouth, tongue ulceration, tooth disorder, tongue problem, mouth ulceration, problems with liver function,</li><li>Skin problem with blisters, hair rash, hair texture abnormal, skin odour abnormal, bone disorder,</li><li>Decreased urination, urinary hesitation, blood in urine,</li><li>Excessive vaginal bleeding, dry vaginal area, red painful penis and foreskin, genital discharge, prolonged erection, breast discharge,</li><li>Hernia, drug tolerance is decreased, diffculty walking, semen abnormal, increase in blood cholesterol levels, injury, and relaxation of blood vessels procedure.</li><li>Cases of suicidal ideation and suicidal behaviours have been reported during sertraline therapy or early after treatment discontinuation (see section 2.).</li></ul><p><strong>After marketing sertraline, the following side effects have been reported:</strong></p><ul><li>Decrease in white blood cells, decrease in clotting cells, endocrine problem, low blood salt, increase in blood sugar levels,</li><li>Terrifying &nbsp;abnormal &nbsp;dreams, suicidal behaviour,</li><li>Muscular movement problems (such as moving a lot, tense muscles, diffculty walking and stiffness, spasms and involuntary movements of the muscles), sudden severe headache (which may be a sign of a serious condition known as Reversible Cerebral Vasoconstriction Syndrome (RCVS)),</li><li>Vision abnormal, unequal sized pupils, bleeding problems (such as stomach bleeding), progressive scarring of lung tissue (Interstitial Lung Disease), pancreatitis, serious liver function&nbsp; problems, &nbsp;yellow skin and eyes (jaundice),</li><li>Skin oedema, skin reaction to sun, muscle cramps, breast enlargement, problems with clotting, abnormal laboratory tests, bedwetting. Light-headedness, fainting, &nbsp;or &nbsp;chest &nbsp;discomfort &nbsp;which &nbsp;could &nbsp;be signs of changes in the electrical activity (seen on electrocardiogram) or abnormal rhythm of the heart.</li></ul><p><strong>Additional side effects in children and adolescents</strong></p><p>In clinical trials with children and adolescents, the side effects were generally similar to adults (see above). The most common side effects in children and adolescents were headache, insomnia, diarrhoea and feeling sick.</p><p><strong>Symptoms that can occur when treatment is discontinued</strong></p><p>If you suddenly stop taking this medicine you may experience side effects such as dizziness, numbness, sleep disturbances, agitation or anxiety, headaches, feeling sick, being sick and shaking (see section 3. &quot;If you stop taking Riasertal&quot;).</p><p>An increased risk of bone fractures has been observed in patients taking this type of medicines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the reach&nbsp; and sight&nbsp; of the children.</p><p>- Store below 30&deg;C</p><p>- Store in the original package in order to protect from light and moisture.</p><p>- Do not use Riasertal after the expiry date, which is stated on the blister or the package.</p><p>- Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>COMPOSITION:</strong></p><p><strong>Tablets:</strong></p><p>Each film-coated tablet contains Sertraline Hydrochloride (Ph Eur) equivalent to Sertraline 50 mg or 100 mg.</p><p>Other ingredients: Microcrystalline Cellulose, Maize Starch, Sodium Starch Glycollate, Talc, Magnesium Stearate and Opadry Blue as film coating.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                PRESENTATION:
Tablets:  
Packs  contain  (30)  film  coated  tablets  of RIASERTAL 50 mg or 100 mg.
Hospital packs of RIASERTAL 50 mg or 100 mg film coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer </strong></p><p>Medical &nbsp;and &nbsp;Cosmetic &nbsp;Products &nbsp;Company &nbsp;Ltd. &nbsp;(Riyadh Pharma)</p><p>P.O.Box 442, Riyadh 11411</p><p>Fax: +966 11 265 0505</p><p>Email: contact@riyadhpharma.com</p><p><em>For any information about this medicinal product, please contact the local representative of marketing&nbsp; authorization holder:&nbsp;</em></p><p>Saudi Arabia</p><p>Riyadh</p><p>Tel: +966 11 265 0111</p><p>&nbsp;Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 10/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>رياسيرتال يحتوي على المادة الفعالة سيرترالين. سيرترالين هو واحد من مجموعة من الأدوية تسمى مثبطات السيروتونين الانتقائية إعادة امتصاص (اس اس اراي)؛ وتستخدم هذه الأدوية لعلاج اضطرابات الاكتئاب و / أو القلق.</p><p><strong>يمكن استخدام رياسيرتال لعلاج:</strong></p><p>الاكتئاب ومنع تكرار الاكتئاب (عند البالغين).</p><p>اضطراب القلق المجتمعي (عند البالغين).</p><p>اضطراب ما بعد الصدمات (PTSD) &nbsp;(عند البالغين).</p><p>اضطراب الهلع (عند البالغين).</p><p>الوسواس القهري (OCD)(في البالغين والأطفال والمراهقين الذين تتراوح أعمارهم بين 6 &ndash; 17 سنة).</p><p>الاكتئاب هو مرض سريري مع أعراض مثل الشعور بالحزن، عدم القدرة على النوم بشكل صحيح أو الاستمتاع بالحياة كالمعتاد.</p><p>اضطرابات الوسواس القهري والذعر أمراض مرتبطة بالقلق مع أعراض مثل أن يكون لديك مشاكل باستمرار أفكار ثابتة (هواجس) تجعلك تقوم بطقوس المتكررة (الالزام).</p><p>اضطراب ما بعد الصدمات هو حالة يمكن أن تحدث بعد تجربة مؤلمة جدا عاطفيا، وبعض الأعراض التي تشبه الاكتئاب والقلق. اضطراب القلق الاجتماعي (الرهاب الاجتماعي) هو مرض مرتبط بالقلق. يتميز بمشاعر القلق الشديد أو ضيق في المواقف الاجتماعية (على سبيل المثال: الحديث مع الغرباء، التكلم أمام مجموعة من الناس، والأكل أو الشرب أمام الآخرين أو القلق أنك قد تتصرف بطريقة محرجة).</p><p>طبيبك قد قرر أن هذا الدواء مناسب لعلاج مرضك.</p><p>يجب عليك أن تسأل طبيبك إذا كنت غير متأكد لماذا تم اعطاءك رياسيرتال</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول رياسيرتال:</strong></p><ul><li>إذا كان لديك حساسية من سيرترالين أو أي من المكونات الأخرى من هذا الدواء (المدرجة في الفقرة 6).</li><li>إذا كنت تتناول أو تناولت الأدوية التي تعرف باسم مثبطات أوكسيديز مثل سيليجيلين، موكلوبميد)&nbsp; &nbsp; أو&nbsp; &nbsp; الادوية الشبيهة ب&nbsp;&nbsp;(مثل لينزوليد). إذا توقفت عن العلاج مع سيرترالين، يجب الانتظار حتى أسبوع واحد على&nbsp;الأقل قبل بدء العلاج مع مثبطات أوكسيديز . بعد وقف العلاج معثبطات أوكسيديز ، يجب عليك الانتظار على الأقل أسبوعين قبل أن تتمكن من بدء العلاج مع سيرترالين.</li><li>إذا كنت تتناول دواء آخر يسمى البيموزيد (دواء لعلاج الاضطرابات النفسية مثل الذهان).</li></ul><p><strong>التحذيرات والاحتياطات</strong></p><p>تحدث إلى طبيبك أو الصيدلاني قبل أخذ رياسيرتال. الأدوية ليست دائما مناسبة للجميع.</p><p>أخبر طبيبك قبل تناول رياسيرتال، إذا كنت تعاني من أو عانيت في الماضي من أي من الحالات التالية:</p><ul><li>إذا كان لديك مرض الصرع (نوبات) أو تاريخ من التشنجات. إذا كان لديك نوبة (تشنج)، اتصل بطبيبك على الفور.</li><li>إذا كنت قد عانيت من مرض الهوس الاكتئابي (اضطراب ثنائي القطب) أو انفصام الشخصية. إذا كان لديك نوبة جنون، اتصل بطبيبك على الفور.</li><li>إذا كان لديك أو كان في السابق أفكار إيذاء أو قتل نفسك، (انظر أدناه-التفكير في الانتحار وتفاقم الاكتئاب أو اضطرابات القلق).</li><li>إذا كان لديك متلازمة السيروتونين. في حالات نادرة، قد تحدث هذه المتلازمة عندما كنت تأخذ أدوية معينة في نفس الوقت سيرترالين. (للأعراض، راجع قسم 4. الآثار الجانبية المحتملة). طبيبك سوف يخبرك ما إذا كنت قد عانيت من هذا في الماضي.</li><li>إذا كان لديك انخفاض بمستوى الصوديوم في الدم، وحيث يمكن أن يحدث هذا نتيجة للعلاج مع رياسيرتال. يجب عليك أيضا إخبار الطبيب إذا كنت تتناول أدوية معينة لارتفاع ضغط الدم، لأن هذه الأدوية يمكن أيضا أن تغير مستوى الصوديوم في الدم.</li><li>إذا كنت من كبار السن لأنك قد تكون أكثر عرضة للخطر من وجود مستوى منخفض الصوديوم في الدم (انظر أعلاه).</li><li>إذا كان لديك مرض في الكبد، فإن طبيبك قد يقرر لك أن تأخذ جرعة أقل من رياسيرتال.</li><li>إذا كان لديك مرض السكري. قد يتم تغيير مستويات الجلوكوز في الدم بسبب رياسيرتال وأدوية السكري الخاصة بك قد تحتاج إلى تعديل.</li><li>إذا كنت قد عانيت من اضطرابات النزيف أو تم أخذ الأدوية التي ترقق الدم (مثل حمض الاسيتيل سالسيليك (الأسبرين)، أو الوارفارين) أو قد يزيد من خطر النزيف.</li><li>إذا كنت طفل أو مراهق تحت 18 سنة. رياسيرتال يجب أن يستخدم فقط لعلاج الأطفال والمراهقين الذين تتراوح أعمارهم بين 6 &ndash; 17 سنة، الذين يعانون من اضطراب الوسواس القهري(OCD)&nbsp;. إذا كنت تعالج لهذا الاضطراب، طبيبك سوف يريد متابعتك عن كثب (أنظر أدناه للأطفال والمراهقين).</li><li>إذا كنت تواجه العلاج بالصعق الكهربائي(ECT)&nbsp; .</li><li>إذا كان لديك مشاكل في العين، مثل أنواع معينة من الجلوكوما (ارتفاع الضغط في العين).</li><li>إذا قيل لك أن لديك خلل في تتبع قلبك بعد رسم القلب&nbsp;(ECG)&nbsp;المعروفة باسم فاصلQT لفترات طويلة.</li></ul><p><strong>الأرق / تعذر الجلوس:</strong></p><p>ارتبط استخدام سيرترالين إلى الأرق المحزن والحاجة للتحرك، في كثير من الأحيان عدم القدرة على الجلوس أو الوقوف دون حراك (تعذر الجلوس). هذا غالبا ما يحدث خلال الأسابيع القليلة الأولى من العلاج. زيادة الجرعة قد تكون ضارة لذلك إذا ظهرت مثل هذه الأعراض يجب عليك التحدث مع طبيبك.</p><p><strong>ردود الفعل الانسحاب: </strong></p><p>الآثار الجانبية المتعلقة بوقف العلاج (ردود فعل الانسحاب) شائعة، لا سيما إذا تم إيقاف العلاج فجأة (انظر القسم 3 إذا توقفت عن تناول رياسيرتال والقسم 4 الآثار الجانبية المحتملة). خطر أعراض الانسحاب يعتمد على طول مدة العلاج والجرعة، والمعدل الذي يتم به تقليل الجرعة. عموما، هذه الأعراض خفيفة الى معتدلة. ومع ذلك، فإنها يمكن أن تكون خطيرة في بعض المرضى. حدوث ذلك عادة يكون في غضون الأيام القليلة الأولى بعد التوقف عن العلاج. بشكل عام، مثل هذه الأعراض تختفي من تلقاء نفسها وتزول في غضون أسبوعين. في بعض المرضى، قد تستمر لفترة أطول (2-3 أشهر أو أكثر). عند ايقاف العلاج مع سيرترالين، فمن المستحسن للحد من الجرعة تدريجيا على مدى فترة تمتد لعدة أسابيع أو أشهر، ويجب أن تناقش دائما أفضل طريقة لوقف العلاج مع الطبيب.</p><p><strong>التفكير في الانتحار وتفاقم الاكتئاب لديك أو اضطرابات القلق:</strong></p><p>إذا كنت مكتئبا و / أو تعاني من اضطرابات القلق، يمكن أن يكون لديك في بعض الأحيان أفكار إيذاء أو قتل نفسك. هذه يمكن أن تزداد عندما بدأت لأول مرة مضادات الاكتئاب، لأن هذه الأدوية كل تستغرق وقتا للعمل، وعادة حوالي أسبوعين لكن في بعض الأحيان لفترة أطول.</p><p><strong>قد تكون أكثر عرضة للتفكير من هذا القبيل:</strong></p><ul><li>إذا كان لديك سبق الأفكار حول قتل أو إيذاء نفسك.</li><li>إذا كنت من الشباب البالغين. وقد أظهرت المعلومات المستسقاة من التجارب السريرية زيادة خطر السلوك الانتحاري لدى البالغين الذين تقل أعمارهم عن 25 عاما ويعانون من حالات نفسية والذين عولجوا مع مضاد للاكتئاب.</li></ul><p>إذا كان لديك أفكار إيذاء أو قتل نفسك في أي وقت، اتصل بطبيبك أو اذهب إلى المستشفى على الفور.</p><p>قد تجد أنه من المفيد لأن تخبر صديق مقرب أو قريب أنك كنت مكتئبا أو لديك اضطرابات القلق، واطلب منهم قراءة هذه النشرة.&nbsp; اطلب منهم ان يخبروك إذا كانوا يعتقدون أن الاكتئاب أو القلق يزداد سوءا، أو إذا انهم قلقون بشأن التغيرات في سلوكك.</p><p><strong>الأطفال والمراهقين:</strong></p><p>لا ينبغي أن يستخدم عادة سيرترالين في الأطفال والمراهقين أقل من 18 عاما، باستثناء المرضى الذين يعانون من اضطراب الوسواس القهري . المرضى الذين تقل أعمارهم عن 18 عرضة لخطر متزايد من آثار غير مرغوب فيها، مثل محاولة الانتحار، والأفكار من إيذاء أو قتل أنفسهم (الأفكار الانتحارية) والعداء (بصفة أساسية العدوانية، والسلوك المعارض والغضب) عندما يتم علاجهم بهذه الفئة من الأدوية. ومع ذلك، فمن الممكن أن يقرر الطبيب أن يصف رياسيرتال لمريض دون سن 18 إذا كان في مصلحة المريض. إذا كان طبيبك وصف لك رياسيرتال وأنت أقل من 18 سنة، وكنت ترغب في مناقشة هذا الموضوع، يرجى الاتصال به / بها. وعلاوة على ذلك، إذا كان أي من الأعراض المذكورة أعلاه تظهر أو تزداد سوءا وأنت تتناول رياسيرتال، يجب إبلاغ الطبيب. أيضا، وحتى الآن لم تثبت سلامة رياسيرتال على المدى الطويل فيما يتعلق بالنمو والنضج والتعلم (الإدراكية) والتنمية السلوكية في هذه الفئة العمرية.</p><p><strong>الأدوية الأخرى ورياسيرتال: </strong></p><p>أخبر طبيبك أو الصيدلي إذا كنت تتناول، قد تناولت مؤخرا أو قد تتناول أي أدوية أخرى.</p><p>بعض الأدوية يمكن أن تؤثر على الطريقة التي يعمل بها رياسيرتال، أو رياسيرتال نفسه يمكن أن يقلل من فعالية الأدوية الأخرى التي تتناولها في الوقت نفسه.</p><p>تناول رياسيرتال جنبا إلى جنب مع الأدوية التالية قد تتسبب في آثار جانبية خطيرة:</p><ul><li>الأدوية التي تعرف باسم مثبطات أوكسيديز MAOI ، مثل موكلوبميد (لعلاج الاكتئاب) وسيليجيلين (لعلاج مرض الشلل الرعاش)، وينزوليد المضادات الحيوية والميثيلين الأزرق (لعلاج ارتفاع مستويات الميتيموغلوبين في الدم). لا تستخدم رياسيرتال جنبا إلى جنب مع هذه الأدوية.</li><li>الأدوية لعلاج الاضطرابات النفسية مثل الذهان (البيموزيد). لا تستخدم رياسيرتال جنبا إلى جنب مع البيموزيد.</li></ul><p><strong>تحدث إلى طبيبك إذا كنت تتناول الأدوية التالية:</strong></p><ul><li>الأدوية العشبية التي تحتوي على نبتة سانت جون (بيرفوراتوم). آثار نبتة سانت جون قد تستمر لمدة 1-2 أسابيع.</li><li>المنتجات التي تحتوي على حمض تريبتوفان الأميني.</li><li>الأدوية لعلاج الألم الشديد (مثل ترامادول).</li><li>الأدوية المستخدمة في التخدير أو لعلاج الألم المزمن (الفنتانيل).</li><li>أدوية علاج الصداع النصفي (مثل سوماتريبتان).</li><li>أدوية ترقيق الدم (الوارفارين).</li><li>الأدوية لعلاج الألم / التهاب المفاصل (الأدوية المضادة للالتهاب غير الستيرويدية (NSAID) مثل ايبوبروفين، حمض اسيتيل سالسيليك (الاسبرين)).</li><li>المهدئات (ديازيبام).</li><li>مدرات البول (وتسمى أيضا أقراص &quot;الماء&quot;).</li><li>أدوية لعلاج الصرع (الفينيتوين، الفينوباربيتال، كربمزبين).</li><li>أدوية لعلاج مرض السكري (تولبوتاميد).</li><li>أدوية لعلاج الحمضية المفرطة في المعدة، والقرحة والحموضة (سيميتيدين، أوميبرازول، لانزوبرازول، بانتوبرازول، الرابيبرازول).</li><li>أدوية لعلاج الهوس والاكتئاب (الليثيوم).</li><li>أدوية أخرى لعلاج الاكتئاب (مثل أميتريبتيلين، نورتريبتيلين، نيفازودون، فلوكستين، فلوفوكسامين).</li><li>أدوية لعلاج الفصام والاضطرابات النفسية الأخرى (مثل بيرفينازين، ليفوميبرومازين والأولانزابين).</li><li>أدوية المستخدمة لعلاج ارتفاع ضغط الدم، وآلام في الصدر أو تنظيم معدل وإيقاع القلب (مثل فيراباميل، ديلتيازيم، فليكانيد، بروبافينون).</li><li>الأدوية المستخدمة لعلاج الالتهابات البكتيرية (مثل ريفامبيسين، كلاريثروميسين، تيليثرومايسين، الاريثروميسين).</li><li>الأدوية المستخدمة لعلاج الالتهابات الفطرية (مثل الكيتوكونازول، الايتراكونازول، بوساكونازول، فوريكونازول، فلوكونازول).</li><li>الأدوية المستخدمة في علاج فيروس نقص المناعة البشرية / الإيدز والتهاب الكبد الوبائي C (مثل مثبطات الأنزيم البروتيني ريتونافير، تيلابريفير).</li><li>الأدوية المستخدمة لمنع الغثيان والقيء بعد العملية أو العلاج الكيميائي (ابريبيتانت).</li><li>الأدوية المعروفة بزيادة مخاطر التغيير في النشاط الكهربائي للقلب (مثل بعض مضادات الذهان ومضادات حيوية).</li></ul><p><strong>رياسيرتال مع الطعام والشراب والكحول:</strong></p><p>يمكن أن تؤخذ أقراص رياسيرتال مع او بدون الطعام.</p><p>وينبغي تجنب الكحول في حين أخذ رياسيرتال.</p><p>لا ينبغي أن يؤخذ سيرترالين بالاقتران مع عصير الجريب فروت، حيث أن ذلك قد يزيد من مستوى سيرترالين في جسمك.</p><p><strong>الحمل، الرضاعة الطبيعية والخصوبة:</strong></p><p>إذا كنتي حاملا أو الرضاعة الطبيعية، تعتقدين أنك قد تكوني حاملا أو تخططين لإنجاب طفل، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p>لم تتقرر بالكامل سلامة سيرترالين في النساء الحوامل. سيتم إعطاء سيرترالين لكي فقط أثناء الحمل إذا رأى الطبيب أن الفائدة لكي أكبر من أي خطر محتمل على الجنين. إذا كنتي امرأة قادرة على الإنجاب يجب عليك استخدام أسلوب يمكن الاعتماد عليه لمنع الحمل (مثل حبوب منع الحمل)، عند تناول سيرترالين.</p><p>تأكدي من أن قابلتك و / أو الطبيب يعرف أنك على رياسيرتال. عند تناوله خلال فترة الحمل، وخصوصا في آخر 3 أشهر من الحمل، الأدوية مثل رياسيرتال قد تزيد من خطر حدوث حالة خطيرة في الأطفال&nbsp;تسمى ارتفاع ضغط (PPHN)،الدم الرئوي المستمر لحديثي الولادة</p><p>مما يجعل الطفل يتنفس بشكل أسرع ويبدو مزرق. تبدأ عادة هذه الأعراض خلال ال 24 ساعة الأولى بعد ولادة الطفل. إذا حدث هذا لطفلك يجب عليك الاتصال قابلتك و / أو الطبيب على الفور.</p><p>الطفل حديث الولادة قد يكون لديه أيضا حالات أخرى، والتي تبدأ عادة خلال ال 24 ساعة الأولى بعد الولادة. وتشمل هذه الأعراض:</p><ul><li>صعوبة في التنفس،</li><li>زرقان الجلد أو أن يكون حاراً أو باردً،</li><li>الشفاه الزرقاء،</li><li>القيء أو عدم التغذية بشكل صحيح،</li><li>أن يكون متعبا جدا، وليس قادرا على النوم أو البكاء الكثير،</li><li>عضلات متصلبة أو لينة،</li><li>اهتزازات، توتر أو تشنجات،</li><li>زيادة ردود الفعل لا ارادياً،</li><li>التهيج،</li><li>انخفاض نسبة السكر في الدم.</li></ul><p>&nbsp;إذا كان طفلك لديه أي من هذه الأعراض عند ولادته، أو كنت قلقة بشأن صحة طفلك&nbsp;فعليك الاتصال بالقابلة أو بالطبيب الذي سيكون قادرا على تقديم النصح.</p><p>هناك أدلة على أن سيرترالين يفرز في حليب الثدي البشري. يجب استخدام سيرترالين فقط في المرأة أثناء الرضاعة، إذا رأى الطبيب أن المنفعة تتجاوز أي خطر محتمل على الجنين.</p><p>بعض الأدوية مثل سيرترالين قد يقلل جودة الحيوانات المنوية في الدراسات الحيوانية. من الناحية النظرية، وهذا قد يؤثر على الخصوبة، ولكن لم يلاحظ تأثير على الخصوبة البشرية حتى الآن.</p><p><strong>القيادة واستخدام الآليات:</strong></p><p>الأدوية النفسية مثل سيرترالين قد تؤثر على قدرتك على القيادة أو استخدام الآلات. بالتالي يتعين عليك عدم قيادة السيارة أو تشغيل الآلات حتى تعرف كيف يؤثر هذا الدواء قدرتك على أداء هذه الأنشطة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائما هذا الدواء تماما كما يخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p><strong>الجرعة الموصي بها هي:</strong></p><p><strong>الكبار:</strong></p><p><strong>الاكتئاب والوسواس القهري</strong></p><p>لعلاج الاكتئاب والوسواس القهري، الجرعة الفعالة المعتادة هي 50 ملجم / يوم. ويمكن زيادة الجرعة بزيادات مقدارها 50 ملجم على فترات من أسبوع واحد على الأقل على مدى أسابيع. والجرعة القصوى الموصي بها هي 200 ملجم / يوم.</p><p><strong>اضطراب الهلع، اضطراب القلق الاجتماعي واضطراب ما بعد الصدمة:</strong></p><p>لاضطرابات الهلع، اضطراب القلق الاجتماعي واضطراب ما بعد الصدمة، وينبغي أن يبدأ العلاج بـ 25 ملجم / يوم، وزيادته إلى 50 ملجم / يوم بعد أسبوع واحد. الجرعة اليومية ثم يمكن زيادتها بزيادات مقدارها 50 ملجم على مدى أسابيع. والجرعة القصوى الموصي بها هي 200 ملجم / يوم.</p><p><strong>الاستخدام في الأطفال و المراهقين&nbsp;</strong></p><p>يجب استخدام رياسيرتال فقط لعلاج الأطفال و المراهقين الذين يعانون من الوسواس القهري الذين تتراوح اعمارهم بين 6-17 سنة .</p><p><strong>الوسواس القهري&nbsp;</strong></p><p><strong>الاطفال الذين تتراوح اعمارهم بين 6 الي 12</strong> : ينبغي ان يبدأ العلاج ب 25 ملجم يومياً.</p><p>بعد اسبوع واحد قد يزيد الطبيب الجرعة الي 50 ملجم يوميا. الجرعة القصوي الموصى هي 200 ملجم يومياً.</p><p><strong>طريقة التناول:</strong></p><p>ويمكن أخذ أقراص رياسيرتال مع أو بدون الطعام.</p><p>تناول الدواء الخاص بك مرة واحدة يوميا إما في الصباح أو في المساء.</p><p>طبيبك سوف ينصحك بمدة تناول هذا الدواء. وهذا يعتمد على طبيعة مرضك جيدا، وكيف كانت الاستجابة للعلاج. قد يستغرق عدة أسابيع قبل أن تبدأ الأعراض في التحسن. علاج الاكتئاب يجب أن يستمر عادة لمدة 6 أشهر بعد التحسن.</p><p><strong>إذا تناولت رياسيرتال أكثر مما يجب:</strong></p><p>إذا كنت&nbsp; تناولت الكثير من رياسيرتال عن غير قصد&nbsp; اتصل بطبيبك على الفور أو اذهب إلى أقرب قسم الطوارئ بالمستشفى. اصطحب معك دائما عبوة الأدوية المعنونة، وما إذا كان هناك أي دواء باقي أو لا.</p><p>ويمكن أن تشمل أعراض الجرعة الزائدة النعاس والغثيان والقيء، وسرعة دقات القلب، والرجفة والاضطراب، والدوخة وفقدان الوعي في بعض الحالات النادرة.</p><p><strong>إذا نسيت أن تأخذ رياسيرتال:</strong></p><p>لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. إذا كنت قد نسيت أن تناول جرعة، لا تأخذ الجرعة المنسية. فقط تناول الجرعة التالية في الوقت المناسب.</p><p><strong>إذا توقفت عن تناول رياسيرتال:</strong></p><p>لا تتوقف عن تناول رياسيرتال إلا إذا طلب منك الطبيب ذلك. طبيبك سيريد تقليل الجرعة تدريجيا من رياسيرتال على مدى عدة أسابيع، قبل أن تتوقف في النهاية تعاطي هذا الدواء. إذا توقفت فجاه عن تعاطي هذا الدواء قد تواجه آثار جانبية مثل الدوخة، وتخدر، واضطرابات النوم والاضطراب أو القلق، والصداع، الشعور بالغثيان، وتوعك وارتجاف. إذا واجهت أي من هذه الآثار الجانبية، أو أي آثار جانبية أخرى أثناء إيقاف تعاطي رياسيرتال، يرجى التحدث إلى طبيبك.</p><p>إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثارا جانبية، وعلى الرغم من أن الجميع لا تحدث لهم.</p><p>الغثيان هو الآثار الجانبية الأكثر شيوعا. الآثار الجانبية تعتمد على الجرعة وغالبا ما تختفي أو تقل مع استمرار العلاج.</p><p><strong>أخبر طبيبك فورا:</strong></p><p>إذا كنت تواجه أي من الأعراض التالية بعد تناول هذا الدواء، ويمكن لهذه الأعراض أن تكون خطيرة.</p><ul><li>إذا تطور لديك الطفح الجلدي الشديد الذي يسبب تقرحات (حمامي عديدة الأشكال)، (وهذا يمكن أن يؤثر على الفم واللسان). قد تكون هذه دلائل على وجود حالة تعرف باسم متلازمة ستيفنز جونسون، أو انحلال البشرة (TEN).السمي</li></ul><p>طبيبك سوف يوقف العلاج في مثل هذه الحالات</p><ul><li>رد فعل تحسسي أو حساسية، والتي قد تشمل أعراض مثل طفح جلدي وحكة في الجلد، ومشاكل في التنفس، أزيز مع التنفس، تورم الجفون والوجه أو الشفتين.</li><li>إذا واجهت الاستثارة، والارتباك، والإسهال، وارتفاع في درجة الحرارة وضغط الدم، التعرق وتسارع في ضربات القلب. هذه أعراض متلازمة السيروتونين. في حالات نادرة قد تحدث هذه المتلازمة عندما تتناول أدوية معينة في نفس الوقت مع سيرترالين. قد يرغب طبيبك لوقف العلاج.</li><li>إذا تطور لديك اصفرار العين والجلد وهو ما قد يعني تلف الكبد.</li><li>إذا عانيت من أعراض الاكتئاب مع أفكار إيذاء أو قتل نفسك (أفكار انتحارية).</li><li>إذا بدأت في الشعور بالقلق ولم تكن قادرا على الجلوس أو الوقوف دون حراك بعد البدء في تناول رياسيرتال. يجب عليك إخبار الطبيب إذا كنت بدأت تشعر أنك لا تهدأ.</li><li>إذا كان لديك نوبة (تشنجات).</li><li>إذا كان لديك نوبة جنون (انظر القسم 2 &quot;تحذيرات واحتياطات&quot;).</li></ul><p><strong>شائعة جدا</strong> (قد تؤثر على أكثر من 1 من كل 10 شخص):</p><p>الأرق، والدوخة، والنعاس والصداع والإسهال، والشعور بالمرض، وجفاف الفم، وعدم القذف، والتعب.</p><p><strong>شائعة </strong>(قد تؤثر على ما يصل إلى 1 من كل 10 شخص):</p><ul><li>التهاب الحلق، وفقدان الشهية، وزيادة الشهية،</li><li>الاكتئاب، والشعور بالغرابة، كابوس، والقلق والاضطراب والعصبية، وانخفاض الاهتمام الجنسي، طحن الأسنان،</li><li>تخدر ووخز، والهز، والعضلات المتوترة، طعم غير طبيعي، وعدم الاهتمام،</li><li>الاضطرابات البصرية، وطنين في الأذنين،</li><li>والخفقان، والاحمرار الساخن، التثاؤب،</li><li>ألم بطني، والتقيؤ، والإمساك واضطرابات المعدة، والغاز،</li><li>الطفح الجلدي، وزيادة التعرق، وآلام في العضلات، ضعف الانتصاب، وآلام في الصدر</li><li>آلام المفاصل،</li><li>التوعك.</li></ul><p><strong>غير شائعة</strong> (قد تؤثر على ما يصل إلى 1 من كل 100 شخص):</p><ul><li>برد الصدر، سيلان الأنف،</li><li>فرط الحساسية،</li><li>انخفاض بهرمونات الغدة الدرقية،</li><li>هلوسة، والشعور بأنك سعيدا جدا، وقلة العناية، والتفكير الشاذ، والعدوان،</li><li>التشنج، وتقلصات العضلات اللاإرادية، والتنسيق الحركي الغير طبيعي، والتحرك الكثير، فقدان الذاكرة، وانخفاض الشعور، اضطراب الكلام، والدوخة عند الوقوف، التوهان، والصداع النصفي،</li><li>اتساع حدقة العين،</li><li>ألم الأذن، سرعة ضربات القلب، وارتفاع ضغط الدم، وبيغ،</li><li>صعوبة في التنفس، من الممكن ازيز مع التنفس، ضيق في التنفس، ونزيف الأنف،</li><li>التهاب المريء وصعوبة في البلع، البواسير، وزيادة اللعاب، واضطراب اللسان، التجشؤ،</li><li>تورم العين، بقع أرجوانية على الجلد والوجه وذمة، وفقدان الشعر، وعرق بارد، وجفاف الجلد، وحمى القش، والحكة،</li><li>التهاب المفاصل، ضعف العضلات، وآلام الظهر، وارتعاش العضلات،</li><li>التبول ليلا، وعدم القدرة على التبول، وزيادة في التبول، وزيادة في تواتر التبول، المشاكل بالتبول، سلس البول،</li><li>النزيف المهبلي، والعجز الجنسي، والعجز الجنسي للإناث، اضطرابات الحيض، وتورم من كل الساقين، وقشعريرة، حمى، ضعف، والعطش، وزيادة في مستويات انزيمات الكبد وانخفاض الوزن، وزيادة الوزن.</li></ul><p><strong>نادرة</strong> (قد يؤثر على ما يصل إلى 1 من كل 1000 شخص):</p><ul><li>مشكلة الأمعاء، التهاب الأذن، والسرطان، تورم الغدد، وارتفاع الكوليسترول في الدم، وانخفاض نسبة السكر في الدم،</li><li>الأعراض الجسدية الناجمة عن الإجهاد أو العواطف، والاعتماد على المخدرات، واضطراب ذهاني، وجنون العظمة، وأفكار انتحارية، المشي أثناء النوم، وسرعة القذف،</li><li>رد فعل تحسسي شديد،</li><li>غيبوبة، حركات غير طبيعية، وصعوبة في تحريك وزيادة الإحساس، واضطراب حسي،</li><li>المياه الزرقاء، مشكلة بالدموع، وبقع أمام العينين، الرؤية المزدوجة والضوء يؤذي العين، والدم في العين، ومشاكل في السيطرة على مستويات السكر في الدم (السكري)،</li><li>نوبة قلبية، وبطء ضربات القلب، مشاكل في القلب وضعف الدورة الدموية في الذراعين والساقين، اغلاق الحلق، سرعة التنفس، والتنفس ببطء وصعوبة في الكلام، الفواق،</li><li>الدم في البراز، والتهاب الفم، وتقرح &nbsp;اللسان، واضطراب الأسنان، مشاكل باللسان، تقرح الفم، ومشاكل في وظائف الكبد،</li><li>مشاكل الجلد مع ظهور بثور، والطفح الجلدي الشعري، نسيج الشعر غير طبيعي، ورائحة الجلد غير طبيعية، واضطرابات العظام،</li><li>انخفاض في التبول، التردد البولي والدم في البول،</li><li>النزيف المهبلي، جفاف منطقة المهبل، احمرار مؤلم للقضيب والقلفة، وإفرازات الأعضاء التناسلية، الانتصاب لفترات طويلة، افرازات من الثدي،</li><li>فتاق، وتناقص تحمل الأدوية، صعوبة في المشي، السائل المنوي غير طبيعي، وزيادة في مستويات الكوليسترول في الدم، والإصابة، والاسترخاء الداخلي بالأوعية الدموية.</li><li>وقد تم الإبلاغ عن حالات التفكير في الانتحار والسلوكيات الانتحارية خلال العلاج سيرترالين أو في وقت مبكر بعد وقف العلاج (انظر القسم 2.).</li></ul><p>&nbsp;</p><p><strong>بعد تسويق سيرترالين، تم الإبلاغ عن الآثار الجانبية التالية:</strong></p><ul><li>انخفاض في خلايا الدم البيضاء، وانخفاض في خلايا التجلط، مشاكل بالغدد الصماء، وانخفاض الملح في الدم، وزيادة في مستويات السكر في الدم،</li><li>أحلام غير طبيعية مرعبة، سلوك انتحاري،</li><li>مشاكل حركة العضلات (مثل التحريك الكثير، توتر العضلات، صعوبة في المشي وصلابة، وتشنجات وحركات لا إرادية للعضلات)، صداع حاد مفاجئ (والذي قد يكون علامة على وجود حالة خطيرة تعرف باسم تضيق الأوعية الدماغية المكتسب الارتجاعي (RCVS))،</li><li>رؤية غير طبيعية، حدقتي العينين غير متساويتا الحجم، ومشاكل النزيف (مثل نزيف المعدة)، تندب تدريجي&nbsp;لأنسجة الرئة (أمراض الرئة الخلالية)، والتهاب البنكرياس، ومشاكل خطيرة بوظائف الكبد، اصفرار العين والجلد (اليرقان)،</li><li>وذمة الجلد، رد فعل الجلد لأشعة الشمس، وتشنجات العضلات، تكبير الثدي، ومشاكل في تخثر الدم، الاختبارات المعملية غير طبيعية، والتبول اللاإرادي. ضعف قوة العزيمة، وإغماء، أو عدم الراحة في الصدر والتي يمكن أن تكون علامات على التغيرات في نشاط القلب الكهربائي (ينظر في تخطيط القلب) أو إيقاع غير طبيعي في القلب.</li></ul><p><strong>آثار جانبية إضافية في الأطفال والمراهقين</strong></p><p>في التجارب السريرية مع الأطفال والمراهقين، وكانت الآثار الجانبية مماثلة عموما للبالغين (انظر أعلاه). وكانت الآثار الجانبية الأكثر شيوعا في الأطفال والمراهقين الصداع، والأرق، والإسهال والشعور بالغثيان.</p><p><strong>الأعراض التي يمكن أن تحدث عند التوقف عن العلاج</strong></p><p>إذا توقفت فجاه عن تناول هذا الدواء قد تواجه آثار جانبية مثل الدوخة، وخدر، واضطرابات النوم والاضطراب أو القلق، والصداع، الشعور بالغثيان، تصبح متوعكا والارتجاف (انظر القسم 3. &quot;إذا توقفت عن تناول رياسيرتال&quot;).</p><p>وقد لوحظ زيادة خطر كسور العظام في المرضى الذين يتناولون هذا النوع من الأدوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- يحفظ بعيدا عن متناول ومرأى الاطفال</p><p>- يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p>- يحفظ في العبوة الأصلية للحماية من الضوء والرطوبة.</p><p>- لا تستخدم رياسيرتال أقراص بعد تاريخ انتهاء الصلاحية المدون على الشريط والعلبة، التاريخ يرجع إلى آخر يوم في هذا الشهر</p><p>- يجب ألا يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه التدابير لحماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحتوي كل قرص مغلف على سيرترالين هيدروكلورايد (دستور الأدوية الأوروبي) ما يعادل سيرترالين 50 ملجم أو 100 ملجم.</p><p>المواد الإضافية: مايكروكريستلين سليلوز، نشا ذرة، صوديوم ستارش جلايكوليت، تالك، مغنيسيوم ستيريت وأوبادري أزرق كمادة مغلفة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>الشكل الصيدلاني:</p><p>أقراص:</p><p>عبوات تحتوي على (30) قرص مغلف من رياسيرتال 50 ملجم أو 100 ملجم. عبوات مستشفيات تحتوي على أقراص مغلفة من رياسيرتال 50 ملجم أو 100 ملجم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>شركة المنتجات الطبية والتجميلية المحدودة (الرياض فارما)</strong></p><p>ص.ب. 442 الرياض 11411</p><p>فاكس: 966112650505+</p><p>البريد الإلكتروني:contact@riyadhpharma.com</p><p><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على&nbsp; صاحب الترخيص والتسويق:</em></p><p>المملكة العربية السعودية</p><p>قسم التسويق</p><p>الرياض</p><p>تلفون: 966112650111+</p><p>البريد الإلكتروني:&nbsp;marketing@riyadhpharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                RIASERTAL 100mg FC TABLET
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet contains 50 mg sertraline (as sertraline hydrochloride).
Film-coated tablet contains 100 mg sertraline (as sertraline hydrochloride).
For a full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Riasertal 50 mg Film coated Tablets: Blue colored, capsules shaped, biconvex film coated tablet with MC20 on one side and break line on the other side.
Riasertal 100 mg Film coated Tablets: Blue colored, capsules shaped, biconvex film coated tablet with MC21 on one side and break line on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sertraline is indicated for the treatment of:<br />Major depressive episodes. Prevention of recurrence of major depressive episodes.<br />Panic disorder, with or without agoraphobia.<br />Obsessive compulsive disorder (OCD) in adults and paediatric patients aged 6-17 years.<br />Social anxiety disorder.<br />Post traumatic stress disorder (PTSD).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sertraline should be administered once daily, either in the morning or evening.<br />Sertraline tablet can be administered with or without food.</p><p><strong>Initial treatment</strong><br /><strong><em>Depression</em> </strong>and OCD<br />Sertraline treatment should be started at a dose of 50 mg/day.<br />Panic Disorder, PTSD, and Social Anxiety Disorder<br />Therapy should be initiated at 25 mg/day. After one week, the dose should be increased to 50 mg once daily. This dosage regimen has been shown to reduce the frequency of early treatment emergent side effects characteristic of panic disorder.</p><p><strong>Titration</strong><br /><strong><em>Depression</em></strong>, OCD, Panic Disorder, Social Anxiety Disorder and PTSD<br />Patients not responding to a 50 mg dose may benefit from dose increases. Dose changes should be made in steps of 50 mg at intervals of at least one week, up to a maximum of 200 mg/day. Changes in dose should not be made more frequently than once per week given the 24-hour elimination half life of sertraline.<br />The onset of therapeutic effect may be seen within 7 days. However, longer periods are usually necessary to demonstrate therapeutic response, especially in OCD.</p><p><strong>Maintenance</strong><br />Dosage during long-term therapy should be kept at the lowest effective level, with subsequent adjustment depending on therapeutic response.<br /><strong><em>Depression</em></strong><br />Longer-term treatment may also be appropriate for prevention of recurrence of major depressive episodes (MDE). In most of the cases, the recommended dose in prevention of recurrence of MDE is the same as the one used during current episode. Patients with depression should be treated for a sufficient period of time of at least 6 months to ensure they are free from symptoms.<br /><em>Panic disorder and OCD</em><br />Continued treatment in panic disorder and OCD should be evaluated regularly, as relapse prevention has not been shown for these disorders.</p><p><strong>Paediatric patients</strong><br /><strong><em>Children and adolescents with obsessive compulsive disorder</em></strong><br />Age 13-17 years: Initially 50 mg once daily.<br />Age 6-12 years: Initially 25 mg once daily. The dosage may be increased to 50 mg once daily after one<br />week.<br />Subsequent doses may be increased in case of less than desired response in 50 mg increments over a period of some weeks, as needed. The maximum dosage is 200 mg daily. However, the generally lower body weights of children compared to those of adults should be taken into consideration when increasing the dose from 50 mg. Dose changes should not occur at intervals of less than one week.<br />Efficacy is not shown in paediatric major depressive disorder.<br />No data is available for children under 6 years of age (see also section 4.4).<br /><em><strong>Use in elderly</strong></em><br />Elderly should be dosed carefully, as elderly may be more at risk for hyponatraemia (see section 4.4).<br /><strong><em>Use in hepatic insufficiency</em></strong><br />The use of sertraline in patients with hepatic disease should be approached with caution. A lower or less frequent dose should be used in patients with hepatic impairment (see section 4.4). Sertraline should not be used in cases of severe hepatic impairment as no clinical data are available (see section 4.4).<br /><strong><em>Use in renal insufficiency</em></strong><br />No dosage adjustment is necessary in patients with renal insufficiency (see section 4.4).<br />Withdrawal symptoms seen on discontinuation of sertraline<br />Abrupt discontinuation should be avoided. When stopping treatment with sertraline the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see sections 4.4 and 4.8). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered.<br />Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to sertraline or to any of the excipients.
Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serotonin syndrome with symptoms such as agitation, tremor and hyperthermia. Sertraline must not be initiated for at least 14 days after discontinuation of treatment with an irreversible MAOI. Sertraline must be discontinued for at least 7 days before starting treatment with an irreversible MAOI (see section 4.5).
Concomitant intake of pimozide is contraindicated (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Serotonin Syndrome (SS) or Neuroleptic Malignant Syndrome (NMS)</strong><br />The development of potentially life-threatening syndromes like serotonin syndrome (SS) or Neuroleptic Malignant Syndrome (NMS) has been reported with SSRIs, including treatment with sertraline. The risk of SS or NMS with SSRIs is increased with concomitant use of serotonergic drugs (including triptans), with drugs which impair metabolism of serotonin (including MAOIs), antipsychotics and other dopamine antagonists. Patients should be monitored for the emergence of signs and symptoms of SS or NMS syndrome (see section 4.3 &ndash; Contraindications).</p><p><strong>Switching from Selective Serotonin Reuptake Inhibitors (SSRIs), antidepressants or antiobsessional drugs</strong><br />There is limited controlled experience regarding the optimal timing of switching from SSRIs, antidepressants or anti-obsessional drugs to sertraline. Care and prudent medical judgment should be exercised when switching, particularly from long-acting agents such as fluoxetine.</p><p><strong>Other serotonergic drugs e.g. tryptophan, fenfluramine and 5-HT agonists</strong><br />Co-administration of sertraline with other drugs which enhance the effects of serotonergic neurotransmission such as tryptophan or fenfluramine or 5-HT agonists, or the herbal medicine, St John&#39;s Wort (hypericum perforatum), should be undertaken with caution and avoided whenever possible due to the potential for a pharmacodynamic interaction.</p><p><strong>Activation of hypomania or mania</strong><br />Manic/hypomanic symptoms have been reported to emerge in a small proportion of patients treated with marketed antidepressant and anti-obsessional drugs, including sertraline. Therefore sertraline should be used with caution in patients with a history of mania/hypomania. Close surveillance by the physician is required. Sertraline should be discontinued in any patient entering a manic phase.</p><p><strong>Schizophrenia</strong><br />Psychotic symptoms might become aggravated in schizophrenic patients.</p><p><strong>Seizures</strong><br />Seizures may occur with sertraline therapy: sertraline should be avoided in patients with unstable epilepsy and patients with controlled epilepsy should be carefully monitored. Sertraline should be discontinued in any patient who develops seizures.</p><p><strong>Suicide/suicidal thoughts/suicide attempts or clinical worsening</strong><br />Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.<br />Other psychiatric conditions, for which sertraline is prescribed, can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.<br />Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.<br />Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p><strong>Use in children and adolescents under 18 years of age</strong><br />Sertraline should not be used in the treatment of children and adolescents under the age of 18 years, except for patients with obsessive compulsive disorder aged 6-17 years old. Suicide-related behaviours (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is<br />nevertheless taken; the patient should be carefully monitored for appearance of suicidal symptoms. In addition, long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking. Physicians must monitor paediatric patients on long term treatment for abnormalities in these body systems.</p><p><strong>Abnormal bleeding/Haemorrhage</strong><br />There have been reports of cutaneous bleeding abnormalities such as ecchymoses and purpura and other hemorrhagic events such as gastrointestinal or gynaecological bleeding, with SSRIs. Caution is advised in patients taking SSRIs, particularly in concomitant use with drugs known to affect platelet function (e.g. anticoagulants, atypical antipsychotics and phenothiazines, most tricyclic antidepressants, acetylsalicylic acid and non-steroidal anti-inflammatory drugs (NSAIDs)) as well as in patients with a history of bleeding disorders (see section 4.5).</p><p><strong>Hyponatraemia</strong><br />Hyponatraemia may occur as a result of treatment with SSRIs or SNRIs including sertraline. In many cases, hyponatraemia appears to be the result of a syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases of serum sodium levels lower than 110 mmol/l have been reported.<br />Elderly patients may be at greater risk of developing hyponatraemia with SSRIs and SNRIs. Also patients taking diuretics or who are otherwise volume-depleted may be at greater risk (see Use in elderly).<br />Discontinuation of sertraline should be considered in patients with symptomatic hyponatraemia and appropriate medical intervention should be instituted. Signs and symptoms of hyponatraemia include headache, difficulty concentrating, memory impairment, confusion, weakness and unsteadiness which may lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.</p><p><strong>Withdrawal symptoms seen on discontinuation of sertraline treatment</strong><br />Withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is abrupt (see section 4.8). In clinical trials, among patients treated with sertraline, the incidence of reported withdrawal reactions was 23% in those discontinuing sertraline compared to 12% in those who continued to receive sertraline treatment.<br />The risk of withdrawal symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor and headache are the most commonly reported reactions. Generally these symptoms are mild to moderate; however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose. Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that sertraline should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&#39;s needs (see section 4.2).</p><p><strong>Akathisia/psychomotor restlessness</strong><br />The use of sertraline has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p><strong>Hepatic impairment</strong><br />Sertraline is extensively metabolised by the liver. A multiple dose pharmacokinetic study in subjects with mild, stable cirrhosis demonstrated a prolonged elimination half life and approximately three-fold greater AUC and Cmax in comparison to normal subjects. There were no significant differences in plasma protein binding observed between the two groups. The use of sertraline in patients with hepatic disease must be approached with caution. If sertraline is administered to patients with hepatic impairment, a lower or less frequent dose should be considered. Sertraline should not be used in patients with severe hepatic impairment (see section 4.2).</p><p><strong>Renal impairment</strong><br />Sertraline is extensively metabolised, and excretion of unchanged drug in urine is a minor route of elimination. In studies of patients with mild to moderate renal impairment (creatinine clearance 30-60ml/min) or moderate to severe renal impairment (creatinine clearance 10-29 ml/min), multiple-dose pharmacokinetic parameters (AUC0-24 or Cmax) were not significantly different compared with controls. Sertraline dosing does not have to be adjusted based on the degree of renal impairment.</p><p><strong>Use in elderly</strong><br />Over 700 elderly patients (&gt;65 years) have participated in clinical studies. The pattern and incidence of adverse reactions in the elderly was similar to that in younger patients. SSRIs or SNRIs including sertraline have however been associated with cases of clinically significant hyponatraemia in elderly patients, who may be at greater risk for this adverse event (see Hyponatraemia in section 4.4).</p><p><strong>Diabetes</strong><br />In patients with diabetes, treatment with an SSRI may alter glycaemic control. insulin and/or oral hypoglycaemic dosage may need to be adjusted.</p><p><strong>Electroconvulsive therapy</strong><br />There are no clinical studies establishing the risks or benefits of the combined use of ECT and sertraline. Grapefruit juice<br />The administration of sertraline with grapefruit juice is not recommended (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Contraindicated</strong><br /><strong><em>Monoamine Oxidase Inhibitors</em></strong><br /><strong><em>Irreversible MAOIs (e.g. selegiline)</em></strong><br />Sertraline must not be used in combination with irreversible MAOIs such as selegiline. Sertraline must not be initiated for at least 14 days after discontinuation of treatment with an irreversible MAOI. Sertraline must be discontinued for at least 7 days before starting treatment with an irreversible MAOI (see section 4.3).<br /><strong><em>Reversible, selective MAO-A inhibitor (moclobemide)</em></strong><br />Due to the risk of serotonin syndrome, the combination of sertraline with a reversible and selective MAOI,&nbsp; such as moclobemide, should not be given. Following treatment with a reversible MAO-inhibitor, a shorter withdrawal period than 14 days may be used before initiation of sertraline treatment. It is recommended that sertraline should be discontinued for at least 7 days before starting treatment with a reversible MAOI (see section 4.3).<br /><em><strong>Reversible, non-selective MAOI (linezolid)</strong></em><br />The antibiotic linezolid is a weak reversible and non-selective MAOI and should not be given to patients treated with sertraline (see section 4.3).<br />Severe adverse reactions have been reported in patients who have recently been discontinued from an MAOI and started on sertraline, or have recently had sertraline therapy discontinued prior to initiation of an MAOI. These reactions have included tremor, myoclonus, diaphoresis, nausea, vomiting, flushing, dizziness, and hyperthermia with features resembling neuroleptic malignant syndrome, seizures, and death.</p><p><strong><em>Pimozide</em></strong><br />Increased pimozide levels of approximately 35% have been demonstrated in a study of a single low dose pimozide (2 mg). These increased levels were not associated with any changes in EKG. While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide, concomitant administration of sertraline and pimozide is contraindicated (see section 4.3).</p><p><strong>Co-administration with sertraline is not recommended</strong><br /><strong><em>CNS depressants and alcohol</em></strong><br />The co-administration of sertraline 200 mg daily did not potentiate the effects of alcohol, carbamazepine, haloperidol, or phenytoin on cognitive and psychomotor performance in healthy subjects; however, the concomitant use of sertraline and alcohol is not recommended.</p><p><strong><em>Other serotonergic drugs</em></strong><br />See section 4.4.<br />Caution is also advised with fentanyl used in general anaesthesia or in the treatment of chronic pain.</p><p><strong>Special Precautions</strong><br /><strong><em>Lithium</em></strong><br />In a placebo-controlled trial in normal volunteers, the co-administration of sertraline with lithium did not significantly alter lithium pharmacokinetics, but did result in an increase in tremor relative to placebo, indicating a possible pharmacodynamic interaction. When co-administering sertraline with lithium, patients should be appropriately monitored.</p><p><strong><em>Phenytoin</em></strong><br />A placebo-controlled trial in normal volunteers suggests that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism. Nonetheless, as some case reports have emerged of high phenytoin exposure in patients using sertraline, it is recommended that plasma phenytoin concentrations be monitored following initiation of sertraline therapy, with appropriate adjustments to the phenytoin dose. In addition, co-administration of phenytoin may cause a reduction of<br />sertraline plasma levels.</p><p><strong><em>Triptans</em></strong><br />There have been rare post-marketing reports describing patients with weakness, hyperreflexia, incoordination, confusion, anxiety and agitation following the use of sertraline and sumatriptan. Symptoms of serotonergic syndrome may also occur with other products of the same class (triptans). If concomitant treatment with sertraline and triptans is clinically warranted, appropriate observation of the patient is advised (see section 4.4).<br /><em><strong>Warfarin</strong></em><br />Co-administration of sertraline 200 mg daily with warfarin resulted in a small but statistically significant increase in prothrombin time, which may in some rare cases unbalance the INR value.<br />Accordingly, prothrombin time should be carefully monitored when sertraline therapy is initiated or stopped.<br /><strong><em>Other drug interactions, digoxin, atenolol, cimetidine</em></strong><br />Co-administration with cimetidine caused a substantial decrease in sertraline clearance. The clinical significance of these changes is unknown. Sertraline had no effect on the beta-adrenergic blocking ability of atenolol. No interaction of sertraline 200 mg daily was observed with digoxin.</p><p><strong><em>Drugs affecting platelet function</em></strong><br />The risk of bleeding may be increased when medicines acting on platelet function (e.g. NSAIDs, acetylsalicylic acid and ticlopidine) or other medicines that might increase bleeding risk are concomitantly administered with SSRIs, including sertraline (see section 4.4).<br /><strong><em>Drugs Metabolized by Cytochrome P450</em></strong><br />Sertraline may act as a mild-moderate inhibitor of CYP 2D6. Chronic dosing with sertraline 50 mg daily showed moderate elevation (mean 23%-37%) of steady-state desipramine plasma levels (a marker of CYP 2D6 isozyme activity). Clinical relevant interactions may occur with other CYP 2D6 substrates with a narrow therapeutic index like class 1C antiarrhythmics such as propafenone and flecainide, TCAs and typical antipsychotics, especially at higher sertraline dose levels. Sertraline does not act as an inhibitor of CYP 3A4, CYP 2C9, CYP 2C19, and CYP 1A2 to a clinically significant degree. This has been confirmed by in-vivo interaction studies with CYP3A4 substrates<br />(endogenous cortisol, carbamazepine, terfenadine, alprazolam), CYP2C19 substrate diazepam, and CYP2C9 substrates tolbutamide, glibenclamide and phenytoin. In vitro studies indicate that sertraline has little or no potential to inhibit CYP 1A2.<br />Intake of three glasses of grapefruit juice daily increased the sertraline plasma levels by approximately 100% in a cross-over study in eight Japanese healthy subjects. Interaction with other CYP3A4 inhibitors has not been established. Therefore, the intake of grapefruit juice should be avoided during treatment with sertraline (see section 4.4). Sertraline plasma levels are enhanced by about 50% in poor metabolizers of CYP2C19 compared to rapid metabolizers (see section 5.2). Interaction with strong inhibitors of CYP2C19 cannot be excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy:</strong><br />Pregnancy category B<br />There are no well controlled studies in pregnant women. However, a substantial amount of data did not reveal evidence of induction of congenital malformations by sertraline. Animal studies showed evidence for effects on reproduction probably due to maternal toxicity caused by the pharmacodynamic action of the compound and/or direct pharmacodynamic action of the compound on the foetus (see 5.3).<br />Use of sertraline during pregnancy has been reported to cause symptoms, compatible with withdrawal reactions, in some neonates, whose mothers had been on sertraline. This phenomenon has also been observed with other SSRI antidepressants. Sertraline is not recommended in pregnancy, unless the clinical condition of the woman is such that the benefit of the treatment is expected to outweigh the potential risk.</p><p>Neonates should be observed if maternal use of sertraline continues into the later stages of pregnancy,<br />particularly the third trimester. The following symptoms may occur in the neonate after maternal sertraline use in later stages of pregnancy: respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying, somnolence and difficulty in sleeping. These symptoms could be due to either serotonergic effects or withdrawal symptoms. In a majority of instances the complications begin immediately or soon (&lt;24 hours) after delivery.<br />Epidemiological data have suggested that the use of SSRIs in pregnancy, particular in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). The observed risk was approximately 5 cases per 1000 pregnancies. In the general population 1 to 2 cases of PPHN per 1000 pregnancies occur.</p><p><strong>Lactation:</strong><br />Published data concerning sertraline levels in breast milk show that small quantities of sertraline and its metabolite N desmethylsertraline are excreted in milk. Generally negligible to undetectable levels were found in infant serum, with one exception of an infant with serum levels about 50% of the maternal level (but without a noticeable health effect in this infant). To date, no adverse effects on the health of infants nursed by mothers using sertraline have been reported, but a risk cannot be excluded. Use in nursing<br />mothers is not recommended unless, in the judgment of the physician, the benefit outweighs the risk. Animal data did not show an effect of sertraline on fertility parameters (see section 5.3.). Human case reports with some SSRIs have shown that an effect on sperm quality is reversible. Impact on human fertility has not been observed so far.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical pharmacology studies have shown that sertraline has no effect on psychomotor performance. However, as psychotropic drugs may impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery, the patient should be cautioned accordingly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nausea is the most common undesirable effect. In the treatment of social anxiety disorder, sexual dysfunction (ejaculation failure) in men occurred in 14% for sertraline vs 0% in placebo. These undesirable effects are dose dependent and are often transient in nature with continued treatment.</p><p>The undesirable effects profile commonly observed in double-blind, placebo-controlled studies in patients with OCD, panic disorder, PTSD and social anxiety disorder was similar to that observed in clinical trials in patients with depression.</p><p><em>Table 1 </em>displays adverse reactions observed from postmarketing experience (frequency not known) and placebo- controlled clinical trials (comprising a total of 2542 patients on sertraline and 2145 on placebo) in depression, OCD, panic disorder, PTSD and social anxiety disorder.</p><p>Some adverse drug reactions listed in Table 1 may decrease in intensity and frequency with continued treatment and do not generally lead to cessation of therapy.</p><p><strong>Table 1: Adverse Reactions</strong></p><p>Frequency of adverse reactions observed from placebo-controlled clinical trials in depression, OCD, panic disorder, PTSD and social anxiety disorder. Pooled analysis and postmarketing experience (frequency not known).</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:96px"><p><strong>Very Common</strong></p><p>(&nbsp;&ge;1/10)</p></td><td style="vertical-align:top; width:125px"><p><strong>Common</strong></p><p>( &ge; 1/100 to &lt;1/10)</p></td><td style="vertical-align:top; width:175px"><p><strong>Uncommon</strong></p><p>( &ge; 1/1000 to</p><p>&lt;1/100)</p></td><td style="vertical-align:top; width:152px"><p><strong>Rare</strong></p><p>( &ge; 1/10000 to &lt;1/1000)</p></td><td style="vertical-align:top"><p><strong>Very. rare</strong></p><p>(&lt;1/10000)</p></td><td style="vertical-align:top"><p><strong>Frequency not Known</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Infections and Infestations</em></p></td></tr><tr><td style="vertical-align:top; width:96px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>Pharyngitis</p></td><td style="vertical-align:top; width:175px"><p>Upper Respiratory Tract Infection, Rhinitis</p></td><td style="vertical-align:top; width:152px"><p>Diverticulitis, Gastroenteritis, Otitis Media</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Neoplasms benign, malignant (including cysts and polyps)</em></p></td></tr><tr><td style="vertical-align:top; width:96px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>&nbsp;</p></td><td style="vertical-align:top; width:175px"><p>&nbsp;</p></td><td style="vertical-align:top; width:152px"><p>Neoplasm&dagger;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Blood and lymphatic system disorders</em></p></td></tr><tr><td style="vertical-align:top; width:96px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>&nbsp;</p></td><td style="vertical-align:top; width:175px"><p>&nbsp;</p></td><td style="vertical-align:top; width:152px"><p>Lymphadenopathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leucopenia, Thrombocytopenia</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Immune system disorders</em></p></td></tr><tr><td style="vertical-align:top; width:96px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>&nbsp;</p></td><td style="vertical-align:top; width:175px"><p>&nbsp;</p></td><td style="vertical-align:top; width:152px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactoid Reaction, Allergic Reaction, Allergy</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Endocrine disorders</em></p></td></tr><tr><td style="vertical-align:top; width:96px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>&nbsp;</p></td><td style="vertical-align:top; width:175px"><p>&nbsp;</p></td><td style="vertical-align:top; width:152px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperprolactinaemia, Hypothyroidism and syndrome of inappropriate ADH secretion</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Metabolism and Nutrition Disorders</em></p></td></tr><tr><td style="vertical-align:top; width:96px"><p>&nbsp;</p></td><td style="vertical-align:top; width:125px"><p>Anorexia, Increased Appetite*</p></td><td style="vertical-align:top; width:175px"><p>&nbsp;</p></td><td style="vertical-align:top; width:152px"><p>Hypercholesterolaemia, Hypoglycaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyponatremia diabetes mellitus, hyperglycaemia</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Psychiatric Disorders</em></p></td></tr><tr><td style="vertical-align:top; width:96px"><p>Insomnia (19%)</p></td><td style="vertical-align:top; width:125px"><p>Depression*, Depersonalisation, Nightmare, Anxiety*, Agitation*, Nervousness, Libido</p></td><td style="vertical-align:top; width:175px"><p>Hallucination*, Euphoric Mood*, Apathy, Thinking Abnormal</p></td><td style="vertical-align:top; width:152px"><p>Conversion Disorder, Drug Dependence, Psychotic disorder*, Aggression*, Paranoia, Suicidal Ideation/behaviour***, Sleep Walking,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Paroniria,</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:159px"><p>&nbsp;</p></td><td style="vertical-align:top; width:92px"><p>Decreased*, Bruxism</p></td><td style="vertical-align:top; width:164px"><p>&nbsp;</p></td><td style="vertical-align:top; width:134px"><p>Premature Ejaculation</p></td><td style="vertical-align:top; width:101px"><p>&nbsp;</p></td><td style="vertical-align:top; width:151px"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Nervous System Disorders</em></p></td></tr><tr><td style="vertical-align:top; width:159px"><p>Dizziness</p></td><td style="vertical-align:top; width:92px"><p>Paraesthesia*,</p></td><td style="vertical-align:top; width:164px"><p>Convulsion*,</p></td><td style="vertical-align:top; width:134px"><p>Coma*,</p></td><td rowspan="25" style="vertical-align:top; width:101px"><p>&nbsp;</p></td><td style="vertical-align:top; width:151px"><p>Movement Disorders</p></td></tr><tr><td style="vertical-align:top; width:159px"><p>(11%),</p></td><td style="vertical-align:top; width:92px"><p>Tremor,</p></td><td style="vertical-align:top; width:164px"><p>Muscle</p></td><td style="vertical-align:top; width:134px"><p>Choreoathetosis,</p></td><td style="vertical-align:top; width:151px"><p>(including</p></td></tr><tr><td style="vertical-align:top; width:159px"><p>Somnolence</p></td><td style="vertical-align:top; width:92px"><p>Hypertonia,</p></td><td style="vertical-align:top; width:164px"><p>Contractions</p></td><td style="vertical-align:top; width:134px"><p>Dyskinesia,</p></td><td style="vertical-align:top; width:151px"><p>extrapyramidal</p></td></tr><tr><td style="vertical-align:top; width:159px"><p>(13%),</p></td><td style="vertical-align:top; width:92px"><p>Dysgeusia,</p></td><td style="vertical-align:top; width:164px"><p>Involuntary*,</p></td><td style="vertical-align:top; width:134px"><p>Hyperaesthesia,</p></td><td style="vertical-align:top; width:151px"><p>symptoms such as</p></td></tr><tr><td style="vertical-align:top; width:159px"><p>Headache</p></td><td style="vertical-align:top; width:92px"><p>Disturbance in</p></td><td style="vertical-align:top; width:164px"><p>Coordination</p></td><td rowspan="21" style="vertical-align:top; width:134px"><p>Sensory Disturbance</p></td><td style="vertical-align:top; width:151px"><p>hyperkinesia,</p></td></tr><tr><td rowspan="20" style="vertical-align:top; width:159px"><p>(21%)*</p></td><td rowspan="20" style="vertical-align:top; width:92px"><p>Attention,</p></td><td style="vertical-align:top; width:164px"><p>Abnormal,</p></td><td style="vertical-align:top; width:151px"><p>hypertonia, teeth</p></td></tr><tr><td style="vertical-align:top; width:164px"><p>Hyperkinesia,</p></td><td style="vertical-align:top; width:151px"><p>grinding or gait</p></td></tr><tr><td style="vertical-align:top; width:164px"><p>Amnesia,</p></td><td style="vertical-align:top; width:151px"><p>abnormalities),</p></td></tr><tr><td style="vertical-align:top; width:164px"><p>Hypoaesthesia*,</p></td><td style="vertical-align:top; width:151px"><p>Syncope.</p></td></tr><tr><td rowspan="16" style="vertical-align:top; width:164px"><p>Speech</p><p>Disorder, Dizziness Postural, Migraine*</p></td><td style="vertical-align:top; width:151px"><p>Also reported were signs and symptoms associated with Serotonin Syndrome or Neuroleptic</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>Malignant</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>Syndrome: In some</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>cases associated with</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>concomitant use of</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>serotonergic drugs</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>that included</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>agitation, confusion,</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>diaphoresis,</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>diarrhoea, fever,</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>hypertension, rigidity</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>and tachycardia.</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>Akathesia and</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>psychomotor</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>restlessness (see</p></td></tr><tr><td style="vertical-align:top; width:151px"><p>section 4.4).</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Eye Disorders</em></p></td></tr><tr><td style="vertical-align:top; width:159px"><p>&nbsp;</p></td><td style="vertical-align:top; width:92px"><p>Visual Disturbance</p></td><td style="vertical-align:top; width:164px"><p>&nbsp;</p></td><td style="vertical-align:top; width:134px"><p>Glaucoma, Lacrimal Disorder, Scotoma, Diplopia, Photophobia, Hyphaema, Mydriasis*</p></td><td style="vertical-align:top; width:101px"><p>&nbsp;</p></td><td style="vertical-align:top; width:151px"><p>Vision Abnormal</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Ear and Labyrinth Disorders</em></p></td></tr><tr><td style="vertical-align:top; width:159px"><p>&nbsp;</p></td><td style="vertical-align:top; width:92px"><p>Tinnitus*</p></td><td style="vertical-align:top; width:164px"><p>Ear Pain</p></td><td style="vertical-align:top; width:134px"><p>&nbsp;</p></td><td style="vertical-align:top; width:101px"><p>&nbsp;</p></td><td style="vertical-align:top; width:151px"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Cardiac Disorders</em></p></td></tr><tr><td style="vertical-align:top; width:159px"><p>&nbsp;</p></td><td style="vertical-align:top; width:92px"><p>Palpitations*</p></td><td style="vertical-align:top; width:164px"><p>Tachycardia</p></td><td style="vertical-align:top; width:134px"><p>Myocardial Infarction, Bradycardia, Cardiac</p></td><td style="vertical-align:top; width:101px"><p>&nbsp;</p></td><td style="vertical-align:top; width:151px"><p>&nbsp;</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:133px"><p>&nbsp;</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td><td style="vertical-align:top; width:150px"><p>&nbsp;</p></td><td style="vertical-align:top; width:135px"><p>Disorder</p></td><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:129px"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Vascular Disorders</em></p></td></tr><tr><td style="vertical-align:top; width:133px"><p>&nbsp;</p></td><td style="vertical-align:top; width:114px"><p>Hot flush*</p></td><td style="vertical-align:top; width:150px"><p>Hypertension*, Flushing</p></td><td style="vertical-align:top; width:135px"><p>Peripheral Ischaemia</p></td><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:129px"><p>Abnormal Bleeding (such as epistaxis, gastrointestinal bleeding or haematuria)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Respiratory, Thoracic, and Mediastinal Disorders</em></p></td></tr><tr><td style="vertical-align:top; width:133px"><p>&nbsp;</p></td><td style="vertical-align:top; width:114px"><p>Yawning*</p></td><td style="vertical-align:top; width:150px"><p>Bronchospasm*, Dyspnoea, Epistaxis</p></td><td style="vertical-align:top; width:135px"><p>Laryngospasm, Hyperventilation, Hypoventilation, Stridor, Dysphonia, Hiccups</p></td><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:129px"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Gastrointestinal Disorders</em></p></td></tr><tr><td style="vertical-align:top; width:133px"><p>Diarrhoea</p></td><td style="vertical-align:top; width:114px"><p>Abdominal Pain*</p></td><td style="vertical-align:top; width:150px"><p>Oesophagitis,</p></td><td style="vertical-align:top; width:135px"><p>Melaena,</p></td><td rowspan="8" style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td rowspan="8" style="vertical-align:top; width:129px"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top; width:133px"><p>(18%),</p></td><td style="vertical-align:top; width:114px"><p>Vomiting*,</p></td><td style="vertical-align:top; width:150px"><p>Dysphagia,</p></td><td style="vertical-align:top; width:135px"><p>Haematochezia,</p></td></tr><tr><td style="vertical-align:top; width:133px"><p>Nausea</p></td><td style="vertical-align:top; width:114px"><p>Constipation*</p></td><td style="vertical-align:top; width:150px"><p>Haemorrhoids,</p></td><td style="vertical-align:top; width:135px"><p>Stomatitis, Tongue</p></td></tr><tr><td style="vertical-align:top; width:133px"><p>(24%), Dry</p></td><td style="vertical-align:top; width:114px"><p>Dyspepsia,</p></td><td style="vertical-align:top; width:150px"><p>Salivary</p></td><td style="vertical-align:top; width:135px"><p>ulceration, Tooth</p></td></tr><tr><td style="vertical-align:top; width:133px"><p>Mouth</p></td><td rowspan="4" style="vertical-align:top; width:114px"><p>Flatulence</p></td><td style="vertical-align:top; width:150px"><p>Hypersecretion,</p></td><td style="vertical-align:top; width:135px"><p>Disorder, Glossitis,</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:133px"><p>(14%)</p></td><td style="vertical-align:top; width:150px"><p>Tongue</p></td><td rowspan="3" style="vertical-align:top; width:135px"><p>Mouth Ulceration</p></td></tr><tr><td style="vertical-align:top; width:150px"><p>Disorder,</p></td></tr><tr><td style="vertical-align:top; width:150px"><p>Eructation</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Hepatobiliary Disorders</em></p></td></tr><tr><td style="vertical-align:top; width:133px"><p>&nbsp;</p></td><td style="vertical-align:top; width:114px"><p>&nbsp;</p></td><td style="vertical-align:top; width:150px"><p>&nbsp;</p></td><td style="vertical-align:top; width:135px"><p>Hepatic Function Abnormal</p></td><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:129px"><p>Serious liver events (including hepatitis, jaundice and liver failure)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Skin and Subcutaneous Tissue Disorders</em></p></td></tr><tr><td style="vertical-align:top; width:133px"><p>&nbsp;</p></td><td style="vertical-align:top; width:114px"><p>Rash*, Hyperhidrosis</p></td><td style="vertical-align:top; width:150px"><p>Periorbital Oedema*, Purpura*, Alopecia*, Cold Sweat, Dry skin, Urticaria*</p></td><td style="vertical-align:top; width:135px"><p>Dermatitis, Dermatitis Bullous, Rash Follicular, Hair Texture Abnormal, Skin Odour Abnormal</p></td><td style="vertical-align:top; width:109px"><p>&nbsp;</p></td><td style="vertical-align:top; width:129px"><p>Rare reports of severe cutaneous adverse reactions (SCAR): e.g.</p><p>Stevens-Johnson syndrome and epidermal necrolysis, Angioedema, Face Oedema, Photosensitivity, Skin Reaction, Pruritus</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6" style="vertical-align:top"><p><em>Musculoskeletal and Connective Tissue Disorders</em></p></td></tr><tr><td style="vertical-align:top; width:126px"><p>&nbsp;</p></td><td style="vertical-align:top; width:103px"><p>Myalgia</p></td><td style="vertical-align:top; width:168px"><p>Osteoarthritis, Muscular Weakness, Back Pain, Muscle Twitching</p></td><td style="vertical-align:top; width:157px"><p>Bone Disorder</p></td><td style="vertical-align:top; width:81px"><p>&nbsp;</p></td><td style="vertical-align:top; width:135px"><p>Arthralgia, Muscle Cramps</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Renal and Urinary Disorders</em></p></td></tr><tr><td style="vertical-align:top; width:126px"><p>&nbsp;</p></td><td style="vertical-align:top; width:103px"><p>&nbsp;</p></td><td style="vertical-align:top; width:168px"><p>Nocturia, Urinary Retention*, Polyuria, Pollakiuria, Micturition disorder</p></td><td style="vertical-align:top; width:157px"><p>Oliguria, Urinary Incontinence*, Urinary Hesitation</p></td><td style="vertical-align:top; width:81px"><p>&nbsp;</p></td><td style="vertical-align:top; width:135px"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Reproductive System and Breast Disorders**</em></p></td></tr><tr><td style="vertical-align:top; width:126px"><p>Ejaculation Failure (14%)</p></td><td style="vertical-align:top; width:103px"><p>Sexual Dysfunction, Erectile Dysfunction</p></td><td style="vertical-align:top; width:168px"><p>Vaginal Haemorrhage, Female Sexual Dysfunction</p></td><td style="vertical-align:top; width:157px"><p>Menorrhagia, Atrophic Vulvovaginitis, Balanoposthitis, Genital Discharge, Priapism*, Galactorrhoea*</p></td><td style="vertical-align:top; width:81px"><p>&nbsp;</p></td><td style="vertical-align:top; width:135px"><p>Gynaecomastia, Menstrual Irregularities</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>General Disorders and Administration Site Conditions</em></p></td></tr><tr><td style="vertical-align:top; width:126px"><p>Fatigue (10%)*</p></td><td style="vertical-align:top; width:103px"><p>Chest Pain*</p></td><td style="vertical-align:top; width:168px"><p>Malaise*, Chills, Pyrexia*, Asthenia*, Thirst</p></td><td style="vertical-align:top; width:157px"><p>Hernia, Injection Site Fibrosis, Drug Tolerance Decreased, Gait Disturbance, Unevaluable Event</p></td><td style="vertical-align:top; width:81px"><p>&nbsp;</p></td><td style="vertical-align:top; width:135px"><p>Oedema Peripheral</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Investigations</em></p></td></tr><tr><td style="vertical-align:top; width:126px"><p>&nbsp;</p></td><td style="vertical-align:top; width:103px"><p>&nbsp;</p></td><td style="vertical-align:top; width:168px"><p>Weight Decreased*, Weight Increased*</p></td><td style="vertical-align:top; width:157px"><p>Alanine Aminotransferase Increased*, Aspartate Aminotransferase Increased*, Semen Abnormal</p></td><td style="vertical-align:top; width:81px"><p>&nbsp;</p></td><td style="vertical-align:top; width:135px"><p>Abnormal Clinical Laboratory Results, Altered Platelet Function, Increased Serum Cholesterol</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Injury and poisoning</em></p></td></tr><tr><td style="vertical-align:top; width:126px"><p>&nbsp;</p></td><td style="vertical-align:top; width:103px"><p>&nbsp;</p></td><td style="vertical-align:top; width:168px"><p>&nbsp;</p></td><td style="vertical-align:top; width:157px"><p>Injury</p></td><td style="vertical-align:top; width:81px"><p>&nbsp;</p></td><td style="vertical-align:top; width:135px"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Surgical and medical procedures</em></p></td></tr><tr><td style="vertical-align:top; width:126px"><p>&nbsp;</p></td><td style="vertical-align:top; width:103px"><p>&nbsp;</p></td><td style="vertical-align:top; width:168px"><p>&nbsp;</p></td><td style="vertical-align:top; width:157px"><p>Vasodilation Procedure</p></td><td style="vertical-align:top; width:81px"><p>&nbsp;</p></td><td style="vertical-align:top; width:135px"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:"Times New Roman";
mso-fareast-theme-font:minor-fareast;mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi;mso-ansi-language:
EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group
 id="_x0000_s1026" style='width:549.1pt;height:169.9pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="10982,3398" o:allowincell="f">
 <v:shape id="_x0000_s1027" style='position:absolute;left:23;top:8;width:20;
  height:3375;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,3375" o:allowincell="f"
  path="m,hhl,3374e" filled="f" strokecolor="#efefef" strokeweight=".28908mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1028" style='position:absolute;left:16;top:15;
  width:10956;height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="10956,20" o:allowincell="f"
  path="m,hhl10955,e" filled="f" strokecolor="#efefef" strokeweight=".28908mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1029" style='position:absolute;left:10965;
  top:8;width:20;height:3375;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,3375" o:allowincell="f"
  path="m,hhl,3374e" filled="f" strokecolor="#a0a0a0" strokeweight=".28908mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1030" style='position:absolute;left:26;top:32;
  width:10940;height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="10940,20" o:allowincell="f"
  path="m,hhl10939,e" filled="f" strokecolor="#a0a0a0" strokeweight=".28908mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1031" style='position:absolute;left:16;top:3381;
  width:24;height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="24,20" o:allowincell="f"
  path="m,hhl23,e" filled="f" strokecolor="#a0a0a0" strokeweight=".58542mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1032" style='position:absolute;left:16;top:3381;
  width:10949;height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="10949,20" o:allowincell="f"
  path="m,hhl10948,e" filled="f" strokecolor="#efefef" strokeweight=".58542mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1033" style='position:absolute;left:33;top:39;
  width:20;height:3327;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,3327" o:allowincell="f"
  path="m,hhl,3326e" filled="f" strokecolor="#a0a0a0" strokeweight=".28908mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1034" style='position:absolute;left:10958;
  top:17;width:20;height:3348;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,3348" o:allowincell="f"
  path="m,hhl,3347e" filled="f" strokecolor="#efefef" strokeweight=".28908mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1035" style='position:absolute;left:30;top:3389;
  width:10942;height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="10942,20" o:allowincell="f"
  path="m,hhl10941,e" filled="f" strokecolor="#a0a0a0" strokeweight=".28908mm">
  <v:path arrowok="t"/>
 </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
  path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1036" type="#_x0000_t202" style='position:absolute;
  left:29;top:24;width:10934;height:3358;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' o:allowincell="f" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:3.25pt;margin-right:21.7pt;
     margin-bottom:0in;margin-left:3.1pt;margin-bottom:.0001pt;line-height:
     100%;punctuation-wrap:simple;mso-line-break-override:restrictions'><i><span
     style='letter-spacing:-.05pt'>If</span><span style='letter-spacing:-.35pt'>
     </span><span style='letter-spacing:-.05pt'>adverse</span><span
     style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.05pt'>experience</span><span
     style='letter-spacing:-.4pt'> </span>occurred<span style='letter-spacing:
     -.35pt'> </span>in<span style='letter-spacing:-.35pt'> </span><span
     style='letter-spacing:-.05pt'>depression,</span><span style='letter-spacing:
     -.4pt'> </span><span style='letter-spacing:-.05pt'>OCD,</span><span
     style='letter-spacing:-.4pt'> </span>panic<span style='letter-spacing:
     -.35pt'> </span><span style='letter-spacing:-.05pt'>disorder,</span><span
     style='letter-spacing:-.4pt'> </span>PTSD<span style='letter-spacing:-.4pt'>
     </span>and<span style='letter-spacing:-.35pt'> </span><span
     style='letter-spacing:-.05pt'>social</span><span style='letter-spacing:
     -.35pt'> </span><span style='letter-spacing:-.05pt'>anxiety</span><span
     style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.05pt'>disorder,</span><span
     style='letter-spacing:-.35pt'> </span>body<span style='letter-spacing:
     5.55pt;mso-font-width:99%'> </span><span style='letter-spacing:-.05pt'>term</span><span
     style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>reclassified</span><span
     style='letter-spacing:-.35pt'> </span>by<span style='letter-spacing:-.45pt'>
     </span>depression<span style='letter-spacing:-.35pt'> </span><span
     style='letter-spacing:-.05pt'>studies</span><span style='letter-spacing:
     -.4pt'> </span>body<span style='letter-spacing:-.4pt'> </span><span
     style='letter-spacing:-.05pt'>term.</span></i></p>
     <p class=MsoBodyText style='margin-top:3.45pt;margin-right:.1in;
     margin-bottom:0in;margin-left:3.1pt;margin-bottom:.0001pt;line-height:
     100%;punctuation-wrap:simple;mso-line-break-override:restrictions'>†<span
     style='letter-spacing:-.2pt'> </span><i><span style='letter-spacing:-.05pt'>One</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>case</span><span
     style='letter-spacing:-.35pt'> </span>of<span style='letter-spacing:-.25pt'>
     </span><span style='letter-spacing:-.05pt'>neoplasm</span><span
     style='letter-spacing:-.3pt'> </span>was<span style='letter-spacing:-.3pt'>
     </span><span style='letter-spacing:-.05pt'>reported</span><span
     style='letter-spacing:-.25pt'> </span>in<span style='letter-spacing:-.25pt'>
     </span>one<span style='letter-spacing:-.35pt'> </span><span
     style='letter-spacing:-.05pt'>patient</span><span style='letter-spacing:
     -.25pt'> </span><span style='letter-spacing:-.05pt'>receiving</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>sertraline</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>compared</span><span
     style='letter-spacing:-.25pt'> </span>with<span style='letter-spacing:
     -.3pt'> </span>no<span style='letter-spacing:-.25pt'> </span><span
     style='letter-spacing:-.05pt'>cases</span><span style='letter-spacing:
     -.25pt'> </span>in<span style='letter-spacing:-.3pt'> </span>the<span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>placebo</span><span
     style='letter-spacing:5.55pt;mso-font-width:99%'> </span><span
     style='letter-spacing:-.05pt'>arm.</span></i></p>
     <p class=MsoBodyText style='margin-top:3.7pt;margin-right:0in;margin-bottom:
     0in;margin-left:3.1pt;margin-bottom:.0001pt;punctuation-wrap:simple;
     mso-line-break-override:restrictions'><i>*<span style='letter-spacing:
     -.4pt'> </span><span style='letter-spacing:-.05pt'>these</span><span
     style='letter-spacing:-.45pt'> </span>adverse<span style='letter-spacing:
     -.4pt'> </span><span style='letter-spacing:-.05pt'>reactions</span><span
     style='letter-spacing:-.3pt'> </span>also<span style='letter-spacing:-.4pt'>
     </span><span style='letter-spacing:-.05pt'>occurred</span><span
     style='letter-spacing:-.35pt'> </span>in<span style='letter-spacing:-.4pt'>
     </span><span style='letter-spacing:-.05pt'>postmarketing</span><span
     style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.05pt'>experience</span></i></p>
     <p class=MsoBodyText style='margin-top:.05in;margin-right:34.8pt;
     margin-bottom:0in;margin-left:3.1pt;margin-bottom:.0001pt;line-height:
     100%;punctuation-wrap:simple;mso-line-break-override:restrictions'><i>**<span
     style='letter-spacing:-.35pt'> </span>the<span style='letter-spacing:-.35pt'>
     </span><span style='letter-spacing:-.05pt'>denominator</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>uses</span><span
     style='letter-spacing:-.2pt'> </span>the<span style='letter-spacing:-.35pt'>
     </span><span style='letter-spacing:-.05pt'>number</span><span
     style='letter-spacing:-.35pt'> </span>of<span style='letter-spacing:-.3pt'>
     </span><span style='letter-spacing:-.05pt'>patients</span><span
     style='letter-spacing:-.3pt'> </span>in<span style='letter-spacing:-.3pt'>
     </span>that<span style='letter-spacing:-.3pt'> </span><span
     style='letter-spacing:-.05pt'>sex</span><span style='letter-spacing:-.35pt'>
     </span><span style='letter-spacing:-.05pt'>group-combined:</span><span
     style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>sertraline</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>(1118</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>males,</span><span
     style='letter-spacing:-.2pt'> </span>1424<span style='letter-spacing:5.35pt;
     mso-font-width:99%'> </span><span style='letter-spacing:-.05pt'>females)</span><span
     style='letter-spacing:-.6pt'> </span><span style='letter-spacing:-.05pt'>placebo</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>(926</span><span
     style='letter-spacing:-.4pt'> </span>males,<span style='letter-spacing:
     -.45pt'> </span>1219<span style='letter-spacing:-.4pt'> </span><span
     style='letter-spacing:-.05pt'>females)</span></i></p>
     <p class=MsoBodyText style='margin-top:.05in;margin-right:0in;margin-bottom:
     0in;margin-left:3.1pt;margin-bottom:.0001pt;punctuation-wrap:simple;
     mso-line-break-override:restrictions'><i>For<span style='letter-spacing:
     -.3pt'> </span><span style='letter-spacing:-.05pt'>OCD,</span><span
     style='letter-spacing:-.35pt'> </span>short<span style='letter-spacing:
     -.25pt'> </span><span style='letter-spacing:-.05pt'>term,</span><span
     style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>1-12</span><span
     style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.05pt'>week</span><span
     style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>studies</span><span
     style='letter-spacing:-.3pt'> </span>only</i></p>
     <p class=MsoBodyText style='margin-top:.05in;margin-right:18.45pt;
     margin-bottom:0in;margin-left:3.1pt;margin-bottom:.0001pt;line-height:
     100%;punctuation-wrap:simple;mso-line-break-override:restrictions'><i>***<span
     style='letter-spacing:-.35pt'> </span>Cases<span style='letter-spacing:
     -.3pt'> </span>of<span style='letter-spacing:-.35pt'> </span><span
     style='letter-spacing:-.05pt'>suicidal</span><span style='letter-spacing:
     -.3pt'> </span><span style='letter-spacing:-.05pt'>ideation</span><span
     style='letter-spacing:-.35pt'> </span>and<span style='letter-spacing:-.3pt'>
     </span><span style='letter-spacing:-.05pt'>suicidal</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>behaviours</span><span
     style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>have</span><span
     style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>been</span><span
     style='letter-spacing:-.3pt'> </span>reported<span style='letter-spacing:
     -.25pt'> </span>during<span style='letter-spacing:-.3pt'> </span><span
     style='letter-spacing:-.05pt'>sertraline</span><span style='letter-spacing:
     -.4pt'> </span><span style='letter-spacing:-.05pt'>therapy</span><span
     style='letter-spacing:-.35pt'> </span>or<span style='letter-spacing:-.3pt'>
     </span><span style='letter-spacing:-.05pt'>early</span><span
     style='letter-spacing:5.35pt;mso-font-width:99%'> </span><span
     style='letter-spacing:-.05pt'>after</span><span style='letter-spacing:
     -.45pt'> </span><span style='letter-spacing:-.05pt'>treatment</span><span
     style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>discontinuation</span><span
     style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>(see</span><span
     style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>section</span><span
     style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>4.4).</span></i></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><em>If adverse experience occurred in depression, OCD, panic disorder, PTSD and social anxiety disorder, body term reclassified by depression studies body term.</em></p><p>&dagger; <em>One case of neoplasm was reported in one patient receiving sertraline compared with no cases in the placebo arm.</em></p><p><em>* these adverse reactions also occurred in postmarketing experience</em></p><p><em>** the denominator uses the number of patients in that sex group-combined: sertraline (1118 males, 1424 females) placebo (926 males, 1219 females)</em></p><p><em>For OCD, short term, 1-12 week studies only</em></p><p><em>*** Cases of suicidal ideation and suicidal behaviours have been reported during sertraline therapy or early after treatment discontinuation (see section 4.4).</em></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:"Times New Roman";
mso-fareast-theme-font:minor-fareast;mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi;mso-ansi-language:
EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:549.1pt;height:169.9pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt'><span style='mso-element:field-begin;mso-field-lock:
yes'></span>SHAPE<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT<span
style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1028" style='width:549.1pt;
 height:169.9pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="10982,3398" o:allowincell="f">
 <v:shape id="_x0000_s1029" style='position:absolute;left:23;top:8;width:20;
  height:3375;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,3375" o:allowincell="f"
  path="m,hhl,3374e" filled="f" strokecolor="#efefef" strokeweight=".28908mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1030" style='position:absolute;left:16;top:15;
  width:10956;height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="10956,20" o:allowincell="f"
  path="m,hhl10955,e" filled="f" strokecolor="#efefef" strokeweight=".28908mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1031" style='position:absolute;left:10965;
  top:8;width:20;height:3375;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,3375" o:allowincell="f"
  path="m,hhl,3374e" filled="f" strokecolor="#a0a0a0" strokeweight=".28908mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1032" style='position:absolute;left:26;top:32;
  width:10940;height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="10940,20" o:allowincell="f"
  path="m,hhl10939,e" filled="f" strokecolor="#a0a0a0" strokeweight=".28908mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1033" style='position:absolute;left:16;top:3381;
  width:24;height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="24,20" o:allowincell="f"
  path="m,hhl23,e" filled="f" strokecolor="#a0a0a0" strokeweight=".58542mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1034" style='position:absolute;left:16;top:3381;
  width:10949;height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="10949,20" o:allowincell="f"
  path="m,hhl10948,e" filled="f" strokecolor="#efefef" strokeweight=".58542mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1035" style='position:absolute;left:33;top:39;
  width:20;height:3327;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,3327" o:allowincell="f"
  path="m,hhl,3326e" filled="f" strokecolor="#a0a0a0" strokeweight=".28908mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1036" style='position:absolute;left:10958;
  top:17;width:20;height:3348;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="20,3348" o:allowincell="f"
  path="m,hhl,3347e" filled="f" strokecolor="#efefef" strokeweight=".28908mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1037" style='position:absolute;left:30;top:3389;
  width:10942;height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="10942,20" o:allowincell="f"
  path="m,hhl10941,e" filled="f" strokecolor="#a0a0a0" strokeweight=".28908mm">
  <v:path arrowok="t"/>
 </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
  path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1038" type="#_x0000_t202" style='position:absolute;
  left:29;top:24;width:10934;height:3358;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' o:allowincell="f" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:3.25pt;margin-right:21.7pt;
     margin-bottom:0in;margin-left:3.1pt;margin-bottom:.0001pt;line-height:
     100%;punctuation-wrap:simple;mso-line-break-override:restrictions'><i><span
     style='letter-spacing:-.05pt'>If</span><span style='letter-spacing:-.35pt'>
     </span><span style='letter-spacing:-.05pt'>adverse</span><span
     style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.05pt'>experience</span><span
     style='letter-spacing:-.4pt'> </span>occurred<span style='letter-spacing:
     -.35pt'> </span>in<span style='letter-spacing:-.35pt'> </span><span
     style='letter-spacing:-.05pt'>depression,</span><span style='letter-spacing:
     -.4pt'> </span><span style='letter-spacing:-.05pt'>OCD,</span><span
     style='letter-spacing:-.4pt'> </span>panic<span style='letter-spacing:
     -.35pt'> </span><span style='letter-spacing:-.05pt'>disorder,</span><span
     style='letter-spacing:-.4pt'> </span>PTSD<span style='letter-spacing:-.4pt'>
     </span>and<span style='letter-spacing:-.35pt'> </span><span
     style='letter-spacing:-.05pt'>social</span><span style='letter-spacing:
     -.35pt'> </span><span style='letter-spacing:-.05pt'>anxiety</span><span
     style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.05pt'>disorder,</span><span
     style='letter-spacing:-.35pt'> </span>body<span style='letter-spacing:
     5.55pt;mso-font-width:99%'> </span><span style='letter-spacing:-.05pt'>term</span><span
     style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>reclassified</span><span
     style='letter-spacing:-.35pt'> </span>by<span style='letter-spacing:-.45pt'>
     </span>depression<span style='letter-spacing:-.35pt'> </span><span
     style='letter-spacing:-.05pt'>studies</span><span style='letter-spacing:
     -.4pt'> </span>body<span style='letter-spacing:-.4pt'> </span><span
     style='letter-spacing:-.05pt'>term.</span></i><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:3.45pt;margin-right:.1in;
     margin-bottom:0in;margin-left:3.1pt;margin-bottom:.0001pt;line-height:
     100%;punctuation-wrap:simple;mso-line-break-override:restrictions'>†<span
     style='letter-spacing:-.2pt'> </span><i><span style='letter-spacing:-.05pt'>One</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>case</span><span
     style='letter-spacing:-.35pt'> </span>of<span style='letter-spacing:-.25pt'>
     </span><span style='letter-spacing:-.05pt'>neoplasm</span><span
     style='letter-spacing:-.3pt'> </span>was<span style='letter-spacing:-.3pt'>
     </span><span style='letter-spacing:-.05pt'>reported</span><span
     style='letter-spacing:-.25pt'> </span>in<span style='letter-spacing:-.25pt'>
     </span>one<span style='letter-spacing:-.35pt'> </span><span
     style='letter-spacing:-.05pt'>patient</span><span style='letter-spacing:
     -.25pt'> </span><span style='letter-spacing:-.05pt'>receiving</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>sertraline</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>compared</span><span
     style='letter-spacing:-.25pt'> </span>with<span style='letter-spacing:
     -.3pt'> </span>no<span style='letter-spacing:-.25pt'> </span><span
     style='letter-spacing:-.05pt'>cases</span><span style='letter-spacing:
     -.25pt'> </span>in<span style='letter-spacing:-.3pt'> </span>the<span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>placebo</span><span
     style='letter-spacing:5.55pt;mso-font-width:99%'> </span><span
     style='letter-spacing:-.05pt'>arm.</span></i><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:3.7pt;margin-right:0in;margin-bottom:
     0in;margin-left:3.1pt;margin-bottom:.0001pt;punctuation-wrap:simple;
     mso-line-break-override:restrictions'><i>*<span style='letter-spacing:
     -.4pt'> </span><span style='letter-spacing:-.05pt'>these</span><span
     style='letter-spacing:-.45pt'> </span>adverse<span style='letter-spacing:
     -.4pt'> </span><span style='letter-spacing:-.05pt'>reactions</span><span
     style='letter-spacing:-.3pt'> </span>also<span style='letter-spacing:-.4pt'>
     </span><span style='letter-spacing:-.05pt'>occurred</span><span
     style='letter-spacing:-.35pt'> </span>in<span style='letter-spacing:-.4pt'>
     </span><span style='letter-spacing:-.05pt'>postmarketing</span><span
     style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.05pt'>experience</span></i><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.05in;margin-right:34.8pt;
     margin-bottom:0in;margin-left:3.1pt;margin-bottom:.0001pt;line-height:
     100%;punctuation-wrap:simple;mso-line-break-override:restrictions'><i>**<span
     style='letter-spacing:-.35pt'> </span>the<span style='letter-spacing:-.35pt'>
     </span><span style='letter-spacing:-.05pt'>denominator</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>uses</span><span
     style='letter-spacing:-.2pt'> </span>the<span style='letter-spacing:-.35pt'>
     </span><span style='letter-spacing:-.05pt'>number</span><span
     style='letter-spacing:-.35pt'> </span>of<span style='letter-spacing:-.3pt'>
     </span><span style='letter-spacing:-.05pt'>patients</span><span
     style='letter-spacing:-.3pt'> </span>in<span style='letter-spacing:-.3pt'>
     </span>that<span style='letter-spacing:-.3pt'> </span><span
     style='letter-spacing:-.05pt'>sex</span><span style='letter-spacing:-.35pt'>
     </span><span style='letter-spacing:-.05pt'>group-combined:</span><span
     style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>sertraline</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>(1118</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>males,</span><span
     style='letter-spacing:-.2pt'> </span>1424<span style='letter-spacing:5.35pt;
     mso-font-width:99%'> </span><span style='letter-spacing:-.05pt'>females)</span><span
     style='letter-spacing:-.6pt'> </span><span style='letter-spacing:-.05pt'>placebo</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>(926</span><span
     style='letter-spacing:-.4pt'> </span>males,<span style='letter-spacing:
     -.45pt'> </span>1219<span style='letter-spacing:-.4pt'> </span><span
     style='letter-spacing:-.05pt'>females)</span></i><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.05in;margin-right:0in;margin-bottom:
     0in;margin-left:3.1pt;margin-bottom:.0001pt;punctuation-wrap:simple;
     mso-line-break-override:restrictions'><i>For<span style='letter-spacing:
     -.3pt'> </span><span style='letter-spacing:-.05pt'>OCD,</span><span
     style='letter-spacing:-.35pt'> </span>short<span style='letter-spacing:
     -.25pt'> </span><span style='letter-spacing:-.05pt'>term,</span><span
     style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>1-12</span><span
     style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.05pt'>week</span><span
     style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>studies</span><span
     style='letter-spacing:-.3pt'> </span>only</i><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.05in;margin-right:18.45pt;
     margin-bottom:0in;margin-left:3.1pt;margin-bottom:.0001pt;line-height:
     100%;punctuation-wrap:simple;mso-line-break-override:restrictions'><i>***<span
     style='letter-spacing:-.35pt'> </span>Cases<span style='letter-spacing:
     -.3pt'> </span>of<span style='letter-spacing:-.35pt'> </span><span
     style='letter-spacing:-.05pt'>suicidal</span><span style='letter-spacing:
     -.3pt'> </span><span style='letter-spacing:-.05pt'>ideation</span><span
     style='letter-spacing:-.35pt'> </span>and<span style='letter-spacing:-.3pt'>
     </span><span style='letter-spacing:-.05pt'>suicidal</span><span
     style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>behaviours</span><span
     style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>have</span><span
     style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.05pt'>been</span><span
     style='letter-spacing:-.3pt'> </span>reported<span style='letter-spacing:
     -.25pt'> </span>during<span style='letter-spacing:-.3pt'> </span><span
     style='letter-spacing:-.05pt'>sertraline</span><span style='letter-spacing:
     -.4pt'> </span><span style='letter-spacing:-.05pt'>therapy</span><span
     style='letter-spacing:-.35pt'> </span>or<span style='letter-spacing:-.3pt'>
     </span><span style='letter-spacing:-.05pt'>early</span><span
     style='letter-spacing:5.35pt;mso-font-width:99%'> </span><span
     style='letter-spacing:-.05pt'>after</span><span style='letter-spacing:
     -.45pt'> </span><span style='letter-spacing:-.05pt'>treatment</span><span
     style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>discontinuation</span><span
     style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>(see</span><span
     style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>section</span><span
     style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.05pt'>4.4).</span></i><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt'><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:549.1pt;
 height:169.9pt'>
 <v:imagedata croptop="-1" cropbottom="1"/>
 <o:lock v:ext="edit" rotation="t" position="t"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Withdrawal symptoms seen on discontinuation of sertraline treatment</strong></p><p>Discontinuation of sertraline (particularly when abrupt) commonly leads to withdrawal symptoms. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor and headache are the most commonly reported. Generally these events are mild to moderate and are self-limiting; however, in some patients they may be severe and/or prolonged. It is therefore advised that when sertraline treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see sections 4.2 and 4.4).</p><p><strong>Elderly population</strong></p><p>SSRIs or SNRIs including sertraline have been associated with cases of clinically significant hyponatraemia in elderly patients, who may be at greater risk for this adverse event (see section 4.4).</p><p><strong>Paediatric population</strong></p><p>In over 600 paediatric patients treated with sertraline, the overall profile of adverse reactions was generally similar to that seen in adult studies. The following adverse reactions were reported from controlled trials (n=281 patients treated with sertraline):</p><p><!--[if gte vml 1]><v:group id="_x0000_s1051"
 style='position:absolute;left:0;text-align:left;margin-left:106.15pt;
 margin-top:7.85pt;width:4.7pt;height:5.8pt;z-index:-251659264;
 mso-position-horizontal-relative:page' coordorigin="2123,157" coordsize="94,116"
 o:allowincell="f">
 <v:shape id="_x0000_s1052" style='position:absolute;left:2131;top:164;width:20;
  height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="20,20" o:allowincell="f"
  path="m,hhl14,e" filled="f" strokeweight=".72pt">
  <v:path arrowok="t"/>
 </v:shape><v:rect id="_x0000_s1053" style='position:absolute;left:2131;top:172;
  width:80;height:100;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' o:allowincell="f" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:5.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><v:shape
      id="_x0000_i1031" type="#_x0000_t75" style='width:4.5pt;height:5.25pt'>
      <v:imagedata src="file:///C:\Users\Emmanuel\AppData\Local\Temp\msohtmlclip1\01\clip_image003.png"
       o:title=""/>
     </v:shape><o:p></o:p></p>
     <p class=MsoNormal><o:p>&nbsp;</o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="9" height="11" src="file:///C:\Users\Emmanuel\AppData\Local\Temp\msohtmlclip1\01\clip_image007.png" /><strong><em>Very common (&nbsp; &ge;&nbsp;</em></strong><strong><em>1/10)</em></strong>: Headache (22%), insomnia (21%), diarrhoea (11%) and nausea (15%).</p><p><!--[if gte vml 1]><v:group id="_x0000_s1054"
 style='position:absolute;left:0;text-align:left;margin-left:83.15pt;
 margin-top:7.6pt;width:4.7pt;height:5.8pt;z-index:-251658240;
 mso-position-horizontal-relative:page' coordorigin="1663,152" coordsize="94,116"
 o:allowincell="f">
 <v:shape id="_x0000_s1055" style='position:absolute;left:1670;top:159;width:20;
  height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="20,20" o:allowincell="f"
  path="m,hhl14,e" filled="f" strokeweight=".72pt">
  <v:path arrowok="t"/>
 </v:shape><v:rect id="_x0000_s1056" style='position:absolute;left:1670;top:166;
  width:80;height:100;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' o:allowincell="f" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:5.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><v:shape
      id="_x0000_i1032" type="#_x0000_t75" style='width:4.5pt;height:5.25pt'>
      <v:imagedata src="file:///C:\Users\Emmanuel\AppData\Local\Temp\msohtmlclip1\01\clip_image003.png"
       o:title=""/>
     </v:shape><o:p></o:p></p>
     <p class=MsoNormal><o:p>&nbsp;</o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="10" height="11" src="file:///C:\Users\Emmanuel\AppData\Local\Temp\msohtmlclip1\01\clip_image008.png" /><strong><em>Common (&nbsp; &ge; 1/100 to &lt;1/10)</em></strong>: Chest pain, mania, pyrexia, vomiting, anorexia, affect lability, aggression, agitation, nervousness, disturbance in attention, dizziness, hyperkinesia, migraine, somnolence, tremor, visual disturbance, dry mouth, dyspepsia, nightmare, fatigue, urinary incontinence, rash, acne, epistaxis, flatulence.</p><p><!--[if gte vml 1]><v:group id="_x0000_s1057"
 style='position:absolute;left:0;text-align:left;margin-left:94.65pt;
 margin-top:7.75pt;width:5.4pt;height:5.8pt;z-index:-251657216;
 mso-position-horizontal-relative:page' coordorigin="1893,155" coordsize="108,116"
 o:allowincell="f">
 <v:shape id="_x0000_s1058" style='position:absolute;left:1900;top:163;width:20;
  height:20;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="20,20" o:allowincell="f"
  path="m,hhl14,e" filled="f" strokeweight=".72pt">
  <v:path arrowok="t"/>
 </v:shape><v:rect id="_x0000_s1059" style='position:absolute;left:1901;top:170;
  width:100;height:100;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' o:allowincell="f" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='mso-line-height-alt:5.0pt;mso-pagination:widow-orphan;
     mso-layout-grid-align:auto;text-autospace:ideograph-numeric ideograph-other'><v:shape
      id="_x0000_i1033" type="#_x0000_t75" style='width:5.25pt;height:5.25pt'>
      <v:imagedata src="file:///C:\Users\Emmanuel\AppData\Local\Temp\msohtmlclip1\01\clip_image009.png"
       o:title=""/>
     </v:shape><o:p></o:p></p>
     <p class=MsoNormal><o:p>&nbsp;</o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><w:wrap anchorx="page"/>
</v:group><![endif]--><strong><img width="10" height="11" src="file:///C:\Users\Emmanuel\AppData\Local\Temp\msohtmlclip1\01\clip_image010.png" /><em>Uncommon ( </em></strong>&nbsp;<strong>&ge;&nbsp;<em><strong>&nbsp;1/1</strong>000 to &lt;1/100)</em>:</strong> ECG QT prolonged, suicide attempt, convulsion, extrapyramidal disorder, paraesthesia, depression, hallucination, purpura, hyperventilation, anaemia, hepatic function abnormal, alanine aminotransferase increased, cystitis, herpes simplex, otitis externa, ear pain, eye pain, mydriasis, malaise, haematuria, rash pustular, rhinitis, injury, weight decreased, muscle twitching, abnormal dreams, apathy, albuminuria, pollakiuria, polyuria, breast pain, menstrual disorder, alopecia, dermatitis, skin disorder, skin odour abnormal, urticaria, bruxism, flushing.</p><p><strong>Frequency not known: enuresis</strong></p><p><strong><em>Class effects</em></strong></p><p>Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this risk is unknown.</p><p><strong>To report any side effects</strong></p><p>-&nbsp;&nbsp; National Pharmacovigilance and Drug Safety Center (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o&nbsp; To call the executive management of vigilance and crisis management: +966-11-2038222 ext.: 2353 &ndash; 2356 &ndash; 2317 &ndash; 2354 &ndash; 2334 &ndash; 234<img width="735" height="3" src="file:///C:\Users\Emmanuel\AppData\Local\Temp\msohtmlclip1\01\clip_image011.png" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt'><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:550.1pt;
 height:1pt'>
 <v:imagedata croptop="-1" cropbottom="1"/>
 <o:lock v:ext="edit" rotation="t" position="t"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>o Toll-free: 8002490000</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Toxicity</strong><br />On the evidence available, sertraline has a wide margin of safety in overdose. Overdoses of sertraline alone of up to 13.5 g have been reported. Deaths have been reported involving overdoses of sertraline, primarily in combination with other drugs and/or alcohol. Therefore, any overdosage should be medically treated aggressively.</p><p><strong>Symptoms</strong><br />Symptoms of overdose include serotonin-mediated side effects such as somnolence, gastrointestinal disturbances (such as nausea and vomiting), tachycardia, tremor, agitation and dizziness. Less frequently reported was coma.</p><p><strong>Treatment</strong><br />There are no specific antidotes to sertraline. Establish and maintain an airway and ensure adequate oxygenation and ventilation, if necessary. Activated charcoal, which may be used with a cathartic, may be as or more effective than lavage, and should be considered in treating overdose. Induction of emesis is not recommended. Cardiac and other vital sign monitoring is recommended, along with general symptomatic and supportive measures. Due to the large volume of distribution of sertraline, forced diuresis, dialysis,<br />haemoperfusion and exchange transfusion are unlikely to be of benefit.<br />Sertraline overdose may prolong the QT-interval, and ECG-monitoring is recommended in all ingestions of sertraline overdoses.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic Group: Antidepressants, Selective serotonin reuptake inhibitor<br />ATC code: N06AB06<br />Sertraline is a potent and specific inhibitor of neuronal serotonin (5 HT) uptake in vitro, which results in the potentiation of the effects of 5-HT in animals. It has only very weak effects on norepinephrine and dopamine neuronal reuptake. At clinical doses, sertraline blocks the uptake of serotonin into human platelets. It is devoid of stimulant, sedative or anticholinergic activity or cardiotoxicity in animals. In controlled studies in normal volunteers, sertraline did not cause sedation and did not interfere with psychomotor performance. In accord with its selective inhibition of 5-HT uptake, sertraline does not enhance catecholaminergic activity. Sertraline has no affinity for muscarinic (cholinergic), serotonergic, dopaminergic, adrenergic, histaminergic, GABA or benzodiazepine receptors. The chronic administration of sertraline in animals was associated with down-regulation of brain norepinephrine receptors as observed with other clinically effective antidepressants and antiobsessional drugs.<br />Sertraline has not demonstrated potential for abuse. In a placebo-controlled, double-blind randomized study of the comparative abuse liability of sertraline, alprazolam and d-amphetamine in humans, sertraline did not produce positive subjective effects indicative of abuse potential. In contrast, subjects rated both alprazolam and d-amphetamine significantly greater than placebo on measures of drug liking, euphoria and abuse potential. Sertraline did not produce either the stimulation and anxiety associated with damphetamine or the sedation and psychomotor impairment associated with alprazolam. Sertraline does not function as a positive reinforcer in rhesus monkeys trained to self administer cocaine, nor does it substitute as a discriminative stimulus for either d-amphetamine or pentobarbital in rhesus monkeys.</p><p><strong>Clinical Trials</strong><br /><strong><em>Major Depressive Disorder</em></strong><br />A study was conducted which involved depressed outpatients who had responded by the end of an initial 8-week open treatment phase on sertraline 50-200 mg/day. These patients (n=295) were randomized to continuation for 44 weeks on double-blind sertraline 50-200 mg/day or placebo. A statistically significantly lower relapse rate was observed for patients taking sertraline compared to those on placebo. The mean dose for completers was 70 mg/day. The % of responders (defined as those patients that did not relapse) for<br />sertraline and placebo arms were 83.4% and 60.8%, respectively.<br /><strong><em>Post traumatic stress disorder (PTSD)</em></strong><br />Combined data from the 3 studies of PTSD in the general population found a lower response rate in males compared to females. In the two positive general population trials, the male and female sertraline vs. placebo responder rates were similar (females: 57.2% vs 34.5%; males: 53.9% vs 38.2%). The number of male and female patients in the pooled general population trials was 184 and 430, respectively and hence the results in females are more robust and males were associated with other baseline variables (more<br />substance abuse, longer duration, source of trauma etc) which are correlated with decreased effect.</p><p><strong><em>Paediatric OCD</em></strong><br />The safety and efficacy of sertraline (50-200 mg/day) was examined in the treatment of non-depressed children (6-12 years old) and adolescent (13-17 years old) outpatients with obsessive compulsive disorder (OCD). After a one week single blind placebo lead-in, patients were randomly assigned to twelve weeks of flexible dose treatment with either sertraline or placebo. Children (6-12 years old) were initially started on a 25 mg dose. Patients randomized to sertraline showed significantly greater improvement than those<br />randomised to placebo on the Children&#39;s Yale-Brown Obsessive Compulsive Scale CY-BOCS (p =0.005) the NIMH Global Obsessive Compulsive Scale (p=0.019), and the CGI Improvement (p =0.002) scales. In addition, a trend toward greater improvement in the sertraline group than the placebo group was also observed on the CGI Severity scale (p=0.089). For CY-BOCs the mean baseline and change from baseline scores for the placebo group was 22.25 &plusmn; 6.15 and -3.4 &plusmn; 0.82, respectively, while for the sertraline group,<br />the mean baseline and change from baseline scores were 23.36 &plusmn; 4.56 and -6.8 &plusmn; 0.87, respectively. In a post-hoc analysis, responders, defined as patients with a 25% or greater decrease in the CY-BOCs (the primary efficacy measure) from baseline to endpoint, were 53% of sertraline-treated patients compared to 37% of placebo-treated patients (p=0.03).<br />Long term safety and efficacy data are lacking for this paediatric population.<br />No data is available for children under 6 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong><br />Sertraline exhibits dose proportional pharmacokinetics in the range of 50 to 200 mg. In man, following an oral once-daily dosage of 50 to 200 mg for 14 days, peak plasma concentrations of sertraline occur at 4.5 to 8.4 hours after the daily administration of the drug. Food does not significantly change the bioavailability of sertraline tablets.</p><p><strong>Distribution</strong><br />Approximately 98% of the circulating drug is bound to plasma proteins.</p><p><strong>Biotransformation</strong><br />Sertraline undergoes extensive first-pass hepatic metabolism.<br />Based on clinical and in-vitro data, it can be concluded that sertraline is metabolized by multiple pathways including CYP3A4, CYP2C19 (see section 4.5) and CYP2B6. Sertraline and its major metabolite desmethylsertraline are also substrate of P-glycoprotein in-vitro.</p><p><strong>Elimination</strong><br />The mean half-life of sertraline is approximately 26 hours (range 22-36 hours). Consistent with the terminal elimination half-life, there is an approximately two-fold accumulation up to steady state concentrations, which are achieved after one week of once-daily dosing. The half-life of N-desmethylsertraline is in the range of 62 to 104 hours. Sertraline and N-desmethylsertraline are both extensively metabolized in man and the resultant metabolites excreted in faeces and urine in equal amounts. Only a small amount (&lt;0.2%) of<br />unchanged sertraline is excreted in the urine.</p><p><strong>Pharmacokinetics in specific patient groups</strong><br /><strong>Paediatric patients with OCD</strong><br />Pharmacokinetics of sertraline was studied in 29 paediatric patients aged 6-12 years old, and 32 adolescent patients aged 13-17 years old. Patients were gradual uptitrated to a 200 mg daily dose within 32 days, either with 25 mg starting dose and increment steps, or with 50 mg starting dose or increments. The 25 mg regimen and the 50 mg regimen were equally tolerated. In steady state for the 200 mg dose, the sertraline plasma levels in the 6-12 year old group were approximately 35% higher compared to the 13-17 year old<br />group, and 21% higher compared to adult reference group. There were no significant differences between boys and girls regarding clearance. A low starting dose and titration steps of 25 mg are therefore recommended for children, especially with low bodyweight. Adolescents could be dosed like adults.</p><p><strong>Adolescents and elderly</strong><br />The pharmacokinetic profile in adolescents or elderly is not significantly different from that in adults between 18 and 65 years.</p><p><strong>Liver function impairment</strong><br />In patients with liver damage, the half life of sertraline is prolonged and AUC is increased three fold (see sections 4.2 and 4.4).</p><p><strong>Renal impairment</strong><br />In patients with moderate-severe renal impairment, there was no significant accumulation of sertraline.</p><p><strong>Pharmacogenomics</strong><br />Plasma levels of sertraline were about 50% higher in poor metabolizers of CYP2C19 versus extensive<br />metabolizers. The clinical meaning is not clear, and patients need to be titrated based on clinical response.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data does not indicate any special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenesis. Reproduction toxicity studies in animals showed no evidence of teratogenicity or adverse effects on male fertility. Observed foetotoxicity was probably related to maternal toxicity. Postnatal pup survival and body weight were decreased only during the first days after birth. Evidence was found that the early postnatal mortality was due to in-utero<br />exposure after day 15 of pregnancy. Postnatal developmental delays found in pups from treated dams were probably due to effects on the dams and therefore not relevant for human risk. Animal data from rodents and non-rodents does not reveal effects on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Core tablets:<br />Microcrystalline cellulose PH 101<br />Maize starch</p><p>Sodium starch glycollate<br />Talc<br />Magnesium stearate<br />Film coating:<br />Opadry Blue YS-IR-4215</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C<br />Store in the original package to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>White transparent PVC/PVDC/Alu foil blister.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep medicine out of reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O. Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing authorization holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                27/11/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>